02/11/2020
Date Journal Title Study type Country Authors Link Trial identifier Intervention Main question
Efficacy of Convalescent To compare the efficacy Plasma Therapy https://www.medrxiv.or and safety of compared to Fresh g/content/10.1101/2020 convalescent plasma with 27 October 2020 MedRxiv Frozen Plasma in Severely RCT India Bajpai et al. NCT04346446 Convalescent plasma .10.25.20219337v1.full.p fresh frozen plasma (FFP) ill COVID-19 Patients: A df in severe COVID-19 Pilot Randomized patients Controlled Trial.
To evaluate the efficacy A placebo-controlled https://www.medrxiv.or and safety of double blind trial of Dubée et al. for the g/content/10.1101/2020 hydroxychloroquine in 21 October 2020 MedRxiv hydroxychloroquine in RCT France HYCOVID study NCT04325893 Hydroxychloroquine .10.19.20214940v1.full.p adult patients with mild- mild-to-moderate COVID- group df to-moderate COVID-19 at 19 risk of worsening.
To evaluate whether early nitazoxanide Early use of nitazoxanide https://www.medrxiv.or therapy would be in mild Covid-19 disease: g/content/10.1101/2020 23 October 2020 MedRxiv RCT Brazil Rocco et al. NCT04552483 Nitazoxanide effective in accelerating randomized, placebo .10.21.20217208v1.full.p symptom resolution in controlled trial df patients with mild COVID- 19.
Controlled randomized To test the combinational clinical trial on using https://www.medrxiv.or therapy of Ivermectin Ivermectin with g/content/10.1101/2020 Ivermectin + and Doxycycline in 27 October 2020 MedRxiv RCT Iraq Hashim et al. NCT04591600 Doxycycline for treating .10.26.20219345v1.full.p Doxycycline treating COVID-19 COVID-19 patients in df patients at different Baghdad, Iraq stages of the disease.
Treatment with human umbilical cord-derived To assess the efficacy and mesenchymal stem cells https://www.medrxiv.or safety of human umbilical human umbilical cord- for COVID-19 patients g/content/10.1101/2020 cord-mesenchymal stem 21 October 2020 MedRxiv RCT China Shi et el. NCT04288102 derived mesenchymal with lung damage: a .10.15.20213553v2.full.p cells (UC-MSCs) to treat stem cells randomised, double- df severe COVID-19 patients blind, placebo-controlled with lung damage. phase 2 trial
Umbilical Cord To determine safety and Mesenchymal Stem Cells https://papers.ssrn.com human umbilical cord- explore efficacy of for COVID-19 ARDS: A 26 October 2020 Lancet pre-print RCT USA Lanzoni et al. /sol3/papers.cfm?abstra NCT04355728 derived mesenchymal Umbilical Cord (UC)-MSC Double Blind, Phase 1/2a, ct_id=3696875 stem cells infusions in COVID-19 Randomized Controlled ARDS. Trial
To determine whether Sofosbuvir/daclatasvir https://academic.oup.co sofosbuvir/daclatasvir- regimens for the 01 November J Antimicrob m/jac/advance- based regimens improve treatment of COVID-19: Meta-analysis UK/Iran Simmons et al. N/A sofosbuvir/daclatasvir 2020 Chemother article/doi/10.1093/jac/ clinical outcomes of an individual patient data dkaa418/5924537 patients with moderate meta-analysis or severe COVID-19. Phase 3 Trial of Coronavir To evaluate the efficacy https://papers.ssrn.com (Favipiravir) in Patients and safety of favipiravir 26 October 2020 Lancet pre-print RCT Russia Ruzhentsova et al. /sol3/papers.cfm?abstra NCT04501783 Favipiravir with Mild to Moderate for treatment of mild to ct_id=3696907 COVID-19 moderate COVID-19
Treatment of Coronavirus Disease 2019 Patients https://www.sciencedire Efficacy of COVID-19 Imunopathology with Convalescent ct.com/science/article/p convalescent plasma November 2020 and infectious RCT USA Salazar et al. Convalescent plasma Plasma Reveals a Signal ii/S0002944020303709? transfusion for severe diseases of Significantly Decreased via%3Dihub and/or critical COVID-19. Mortality
Efficacy of Tocilizumab in https://www.nejm.org/d Does tocilizumab prevent 21 October 2020 NEJM Patients Hospitalized with RCT USA Stone et al. oi/pdf/10.1056/NEJMoa NCT04356937 Tocilizumab intubation or death? Covid-19 2028836
Effect of Tocilizumab vs To determine whether Usual Care in Adults https://jamanetwork.co tocilizumab (TCZ) JAMA Internal Hospitalized With COVID- m/journals/jamainternal improves outcomes of 20 October 2020 RCT France Hermine et al. NCT04331808 Tocilizumab Medicine 19 and Moderate or medicine/fullarticle/277 patients hospitalized with Severe Pneumonia: A 2187 moderate-to-severe Randomized Clinical Trial COVID-19 pneumonia
Effect of Tocilizumab vs Standard Care on Clinical https://jamanetwork.co NCT04346355; To evaluate the effect of JAMA Internal Worsening in Patients m/journals/jamainternal EudraCT 20 October 2020 RCT Italy Salvarani et al. Tocilizumab early tocilizumab Medicine Hospitalized With COVID- medicine/fullarticle/277 Identifier: 2020- administration 19 PneumoniaA 2186 001386-37. Randomized Clinical Trial
International Efficacy of umifenovir in To evaluate the efficacy Journal of https://pharmascope.or the treatment of mild and Randomized of umifenovir in mild and 01 October 2020 Research in Kyrgizstan Yethindra et al. g/ijrps/article/view/283 NA Umifenovir moderate covid-19 clinical study moderate COVID-19 Pharmaceutical 9/6116 patients patients Sciences
To evaluate the efficacy Remdesivir for the https://www.nejm.org/d of remdesivir in 8 October 2020 NEJM Treatment of Covid-19 — RCT USA John H. Beigel, et al. oi/10.1056/NEJMoa2007 NCT04280705 Remdesivir shortening time to Final Repor 764 recovery in hospitalized COVID-19 patients. Safety and immunogenicity of an https://www.sciencedire To assess the safety and inactivated SARS-CoV-2 Phase 1/2 ct.com/science/article/p ChiCTR2000032 immunogenicity of an 15 October 2020 Lancet vaccine, BBIBP-CorV: a China Shengli Xia, et al. BBIBP-CorV vaccine trial ii/S1473309920308318? 459. inactivated SARS CoV2 randomised, double- via%3Dihub vaccine blind, placebo-controlled, phase 1/2 trial
Repurposed antiviral Lopinavir/ritonavir, https://www.medrxiv.or Are repurposed andiviral drugs for COVID-19 Internation Hongchao Pan, et ISRCTN8397115 remdesivir, 15 October 2020 MedRiXV RCT g/content/10.1101/2020 drugs effective in treating –interim WHO al al. 1 hydroxychloroquine, .10.15.20209817v1 COV ID19? SOLIDARITY trial results interferon
To assess the safety and dose response through SARS-CoV-2 Neutralizing https://www.nejm.org/d reduction of viral load of Antibody LY-CoV555 in Monoclonal antibody, 28 October 2020 NEJM Phase 2 RCT USA Peter Chen, et al. oi/10.1056/NEJMoa2029 NCT04427501 monoclonal antibody LY- Outpatients with Covid- LY-CoV555 849 CoV555 in patients with 19 mild or moderate COVID- 19
To assess if a simple incentive to self-prone Self-Proning in COVID-19 for a maximum of 12 h Patients on Low-Flow https://papers.ssrn.com per day would decrease Switzerlan SNCTP00000371 21 October 2020 Lancet preprint Oxygen Therapy: A RCT Aileen Kharat, et al. /sol3/papers.cfm?abstra Self-proning oxygen needs in patients d 8 Cluster Randomised ct_id=3692538 admitted for COVID-19 Controlled Trial pneumonia on low-flow oxygen therapy.
Interim analysis of an To assess if nasal open-label randomized irrigation can reduce International controlled trial evaluating https://onlinelibrary.wil 11 September Kyle S. Kimura, et symptoms and viral Forum of Allergy nasal irrigations in RCT USA ey.com/doi/10.1002/alr. NA Nasal irrigations 2020 al. shedding in mild and and Rhinology non-hospitalized patients 22703 moderate COVID-19 with coronavirus disease patients 2019 To assess the safety and Tocilizumab in https://www.medrxiv.or efficacy of tocilizumab in nonventilated patients Preprint MedRiXV RCT USA Carlos Salama, et al. g/content/10.1101/2020 NCT04372186 Tocilizumab patients hospitalized and hospitalized with Covid- .10.21.20210203v1 non-ventilated with Covid- 19 pneumonia 19 pneumonia.
The use of intravenous immunoglobulin gamma To evaluate the efficacy for the treatment of https://bmcinfectdis.bio of intravenous BMC Infectious severe coronavirus Naser Gharebaghi, medcentral.com/articles IRCT202005010 Immunoglobulin 21 October 2020 RCT Iran immunoglobulin (IVIg) in Diseases disease 2019: a et al. /10.1186/s12879-020- 47259N1 gamma patients with severe randomized placebo- 05507-4 COVID-19 infection. controlled double-blind clinical trial
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive Phase 2 study to explore https://www.thelancet.c care for patients with the potential benefit and 28 September Netherland Alexander P J Vlaar, om/action/showPdf?pii= Lancet severe COVID-19 RCT NCT04333420 Vilobelimab safety of IFX-1 2020 s et al. S2665- (PANAMO): an (vilobelimab) in patients 9913%2820%2930341-6 exploratory, open-label, with severe COVID-19. phase 2 randomised controlled trial
Is the SARS CoV-2 mRNA Safety and https://www.nejm.org/d 1273 safe and well 29 September Immunogenicity of SARS- Vaccine trial Evan J. Anderson, et NEJM USA oi/full/10.1056/NEJMoa NCT04283461 mRNA-1273 vaccine tolerated in older adults 2020 CoV-2 mRNA-1273 Phase 1 al. 2028436 and does it ellicit an Vaccine in Older Adults immune response?
Does the BNT162b1 COVID-19 vaccine 30 September https://www.nature.co vaccine elicit both BNT162b1 elicits human Vaccine trial 2020 -pre- Nature Germany Ugur Sahin, et al. m/articles/s41586-020- NCT04380701 BNT162b1 vaccine antibody and T-cell antibody and TH1 T-cell Phase 1 and 2 approved 2814-7 response in healthy responses adults? To evaluate the efficacy and safety of Engineered interferon https://assets.researchs recombinant super- alpha effectively quare.com/files/rs- ChiCTR2000029 Engineered interferon compound interferon Preprint Research Square improves clinical RCT China Chuan Li, et al. 65224/v1/22886bf0- 638 alpha versus traditional outcomes of COVID-19 ce06-4d42-aeb6- interferon alpha in patients c73ebb7c2003.pdf patients with moderate to severe COVID-19
To evaluate the efficacy Interferonβ-1b in https://www.sciencedire International and safety of interferon treatment of severe Hamid Rahmani, et ct.com/science/article/p IRCT201002280 24 August 2020 Immunopharmacol RCT Iran Interferon β-1b (IFN) β-1b in the COVID-19: A randomized al. ii/S1567576920323304? 03449N27 ogy treatment of patients clinical trial via%3Dihub with severe COVID-19
To evaluate the efficacy of hydroxychloroquine to Efficacy and Safety of prevent transmission of Hydroxychloroquine vs https://jamanetwork.co SARS-CoV-2 in hospital- 30 September Placebo for Pre-exposure Benjamin S Abella, m/journals/jamainternal JAMA RCT USA NCT04329923 Hydroxychloroquine based HCWs with 2020 SARS-CoV-2 Prophylaxis et al. medicine/fullarticle/277 exposure to patients with Among Health Care 1265 COVID-19 using a pre- Workers exposure prophylaxis strategy
Drug treatments for covid- Internation To compare the effects of 4 September 19: living systematic Systematic al Reed AC https://www.bmj.com/c treatments for BMJ NA All treatments 2020 review and review collaborati Siemieniuk, et al. ontent/370/bmj.m2980 coronavirus network meta-analysis on disease 2019 (covid-19).
To compare the rate of clinical improvement Effect of remdesivir on among patients with patients with COVID-19: https://www.ncbi.nlm.ni COVID-19 who received 5- 15-oct Virus Research A network meta-analysis Meta-analysis USA, Japan Yokoyama et al. h.gov/pmc/articles/PMC N/A Remdesivir day course of remdesivir of randomized control 7437510/pdf/main.pdf versus 10-day course of trials remdesivir versus standard care.
To investigate the safety and immunogenicity of An in-depth investigation an inactivated viral https://www.medrxiv.or of the safety and vaccine in immunized g/content/10.1101/2020 06-sept MedRxiv immunogenicity of an Phase 1 RCT China Pu et el. NCT04412538 Vaccine individuals in a phase I .09.27.20189548v1.full.p inactivated 2 SARS-CoV-2 trial, especially focusing df vaccine on safety with regard to the immunopathology of the vaccine.
Clearing the fog: Is Hydroxychloroquine https://www.medrxiv.or To assess the efficacy of effective in reducing Mehmood Kamran g/content/10.1101/2020 HCQ in reducing disease 11-oct MedRxiv Corona virus disease- RCT Pakistan NCT04491994 Hydroxychloroquine et al. .07.30.20165365v2.full.p progression in mild 2019 progression: A df COVID-19 randomized controlled trial Lopinavir–ritonavir in Whether https://www.thelancet.c patients admitted to ISRCTN lopinavir–ritonavir hospital with COVID-19 Horby et al. om/action/showPdf?pii= 05-oct-20 The Lancet RCT UK 50189673, lopinavir/ritonavir improves outcomes in (RECOVERY): a randomised, (RECOVERY GROUP) S0140- NCT04381936 patients admitted to controlled, open-label, 6736%2820%2932013-4 platform trial hospital with COVID-19
An open-label, randomized https://www.sciencedire trial of the combination of Efficacy and safety of IFN- IFN-kappa plus TFF2 with ct.com/science/article/p ChiCTR2000030 20-sept-20 EClinicalMedicine RCT China Fu et al. IFN-κ , TFF2 κ and TFF2 in COVID standard care in the ii/S2589537020302911? 262 patients. treatment of patients with via%3Dihub moderate COVID-19
Safety and Vaccine: non- immunogenicity of the replicating adenovirus Ad26.COV2.S COVID-19 https://www.medrxiv.or Netherland 26 based vector To evaluate the efficacy vaccine candidate: g/content/10.1101/2020 25-sept MedRxiv Phase 1/2a RCT s, Belgium, Sadoff et al. NCT04436276 expressing the of a single vaccination of interim results of a phase .09.23.20199604v1.full.p USA stabilized pre-fusion 5x1010 vp of Ad26.COV2.S 1/2a, double-blind, df spike protein of SARS- randomized, placebo- CoV-2 controlled trial
To determine the Hydroxychloroquine as effectiveness of https://www.medrxiv.or pre-exposure prophylaxis hydroxychloroquine as g/content/10.1101/2020 21-sept MedRxiv for COVID-19 in RCT USA Rajasingham et al. NCT04328467 Hydroxychloroquine pre-exposure prophylaxis .09.18.20197327v1.full.p healthcare workers: a in healthcare workers at df randomized trial high-risk of SARS-CoV-2 exposure
Treatment with an Anti- CK2 Synthetic Peptide https://www.medrxiv.or To explore safety and Improves Clinical 3 IG/CIGB300I/CV g/content/10.1101/2020 Anti-CK2 Synthetic efficacy of CIGB-325, an 22-sept MedRxiv Response in Covid-19 RCT Cuba Cruz et al. /2001, ATENEA- .09.03.20187112v2.full.p Peptide, CIGB-325 anti-CK2 peptide, in Patients with Pneumonia. Co-300 trial df COVID-19 patients. A Randomized and 4 Controlled Clinical Trial
To compare the rate of clinical improvement Effect of remdesivir on https://www.sciencedire among patients with patients with COVID-19: Yujiro Yokoyama et ct.com/science/article/p COVID-19 who received 5- 15-oct Virus Research A network meta-analysis Meta-analysis USA, Japan N/A Remdesivir al. ii/S0168170220310443? day course of remdesivir of randomized control via%3Dihub versus 10-day course of trials remdesivir versus standard care. Remdesivir for Severe https://academic.oup.co NCT04292899 Clinical Infectious COVID-19 versus a Cohort Susan A. Olender, m/cid/advance- Efficacy of remdesivir in 24 July 2020 RCT vs cohort USA and Remdesivir Diseases Receiving Standard of et al. article/doi/10.1093/cid/ COVID19 patients EUPAS34303 Care ciaa1041/5876045
Assess the efficacy of A prospective, favipiravir in Antimicrobial randomized, open-label https://aac.asm.org/con asymptomatic or mild Preprint Agents trial of early versus late RCT Japan Yohei Doi, et al. tent/early/2020/09/16/ Favipiravir jRCTs041190120 COVID19 patients in viral Chemotherapy favipiravir in hospitalized AAC.01897-20 clearance, and resolution patients with COVID-19 of symptoms
Favipiravir versus other antiviral or standard of https://virologyj.biomed To evaluate the efcacy Systematic care for COVID-19 Dhan Bahadur central.com/articles/10. and safety of the drug 24-sept Virology Journal review & meta- Nepal N/A Favipiravir treatment: a rapid Shrestha et al. 1186/s12985-020-01412- Favipiravir as a treatment analysis systematic review and z for COVID-19. meta-analysis
Therapeutic versus To compare therapeutic prophylactic https://www.thrombosis Anna Cristina enoxaparin treatment to 20 September Thrombosis anticoagulation for research.com/article/S0 REBEC RBR- Enoxaparin, RCT Brazil Bertoldi Lemos, et standard prophylactic 2020 Research severe COVID-19: A 049-3848(20)30530- 949z6v anticoagulants al. anticoagulant treatment randomized phase II 2/fulltext#%20 in severe COVID19 clinical trial (HESACOVID)
Treatment of COVID-19 To evaluate the efficacy Patients with Prolonged https://academic.oup.co and safety of leflunomide Post-Symptomatic Viral Clinical Infectious m/cid/advance- ChiCTR to treat COVID-19 Preprint Shedding with RCT China Wang, et al Leflunomide Diseases article/doi/10.1093/cid/ 2000030058 patients with prolonged Leflunomide -- a Single- ciaa1417/5909448 post-symptomatic viral Center, Randomized, shedding. Controlled Clinical Trial Effect of hydroxychloroquine with To assess the effect of https://www.clinicalmicr or without azithromycin chloroquine and Clinical Systematic France, obiologyandinfection.co Chloroquine, on the mortality of Thibault Fiolet, et hydroxychloroquine with 26 August 2020 Microbiology and Review and Switzerlan m/article/S1198- NA hydroxychloroquine, coronavirus disease 2019 al. or without azithromycin Infection Meta-analysis d 743X(20)30505- azithromycin (COVID-19) patients: a on the mortality of COVID- X/fulltext systematic review and 19 patients meta-analysis
Efficacy of commercial To evaluate and compare mouth-rinses on SARS- Chaminda https://www.medrxiv.or different commercial Preprint MedRxIV CoV-2 viral load in saliva: RCT Singapore Jayampath g/content/10.1101/2020 NA Mouth wash moutwash solutions and Randomized Control Trial Seneviratne, et al. .09.14.20186494v1 their effect on reducing in Singapore salivary viral load
Early Anti-SARS-CoV-2 Evaluate the safety and Convalescent Plasma in https://www.medrxiv.or efficacy of convalescent María Elvira Preprint MedRxIV Patients Admitted for RCT Chile g/content/10.1101/2020 NCT04375098 Covalescent Plasma plasma and compare an Balcells, et al. COVID-19: A Randomized .09.17.20196212v1 early vs deferred Phase II Clinical Trial treatement strategy
Evaluate the efficacy of Effect of bromhexine on bromhexine in intensive clinical outcomes and https://bi.tbzmed.ac.ir/ IRCT202003117 care unit (ICU) admission, 19 July 2020 Bioimpacts mortality in COVID-19 RCT Iran Khalil Ansarin Bromhexine Article/bi-23240 046797N4 mechanical ventilation, patients: A randomized and mortality in patients clinical trial with COVID-19.
Identify studies https://www.tandfonlin Expert Review of The effect of antivirals on pertaining to antivirals in Systematic Hussain et e.com/doi/abs/10.1080/ 12-sept-20 Anti-Infective COVID-19: a systematic UK NA Antivirals COVID-19 patients and review al. 14787210.2021.1823832 Therapy review review the clinical ?journalCode=ierz20 outcomes
Double-blind, randomized, placebo- controlled trial with N- https://academic.oup.co To determine whether 23 September Clinical Infectious acetylcysteine for Julio Cesar Garcia m/cid/advance- NAC in high doses can RCT Brazil 2020 Diseases treatment of severe de Alencar, et al. article/doi/10.1093/cid/ avoid respiratory failure acute respiratory ciaa1443/5910353 in patients with Covid-19. syndrome caused by COVID-19 Intravenous methylprednisolone pulse as a treatment for https://erj.ersjournals.c European Is methylprednisolone hospitalised severe om/content/early/2020/ IRCT202004040 17-sept-20 Respiratory RCT Iran Edalatifard et al. Methylprednisolone effective in treatment of COVID-19 patients: 09/09/13993003.02808- 46947N1 Journal COVID-19 patients? results from a 2020 randomised controlled clinical trial
Interventions for treatment of COVID-19: A https://journals.plos.org Effects of all treatment living systematic review /plosmedicine/article?id 17-sept-20 Plos Medicine Meta-analysis Denmark Juul et al. NA NA interventions for COVID- with meta-analyses and =10.1371/journal.pmed. 19 trial sequential analyses 1003293 (The LIVING Project)
Safety and immunogenicity of an rAd26 and rAd5 vector- https://www.sciencedire Safety and based heterologous NCT04436471 ct.com/science/article/p immunogenicity of two 04-sept-20 The Lancet prime-boost COVID-19 CT Russia Logunov et al. and vaccine ii/S0140673620318663? formulations (frozen and vaccine in two NCT04437875 via%3Dihub lyophilised) of vaccine formulations: two open, non-randomised phase 1/2 studies from Russia
Safety and effectiveness International https://www.sciencedire Can therapy with of azithromycin in Journal of ct.com/science/article/p HCQ+AZM reduce the 01-oct-20 patients with COVID-19: RCT Iran Sekhavati et al. NA azithromycine Antimicrobial ii/S0924857920303411? hospital length of stay in An open-label Agents via%3Dihub COVID-19 patients? randomised trial
Effect of Recombinant Human Granulocyte Do increased peripheral Colony–Stimulating https://jamanetwork.co blood leukocyte and Factor for Patients With m/journals/jamainternal ChiCTR2000030 lymphocyte cell counts 10-sept-20 JAMA RCT China Cheng et al. G-CSF Coronavirus Disease 2019 medicine/fullarticle/277 007 lead to clinical (COVID-19) and 0680 improvement in patients Lymphopenia: A with COVID-19? Randomized Clinical Trial Azithromycin in addition to standard of care versus standard of care https://www.thelancet.c Would azithromycine alone in the treatment of om/action/showPdf?pii= improve clinical 04-sept-20 The Lancet patients admitted to the RCT Brazil Furtado et al. NCT04321278 azithromycine S0140- outcomes to COVID-19 hospital with severe 6736%2820%2931862-6 patiets? COVID-19 in Brazil (COALITION II): a randomised clinical trial
Is the use of CQ or HCQ Chloroquine and effective and safe in Hydroxychloroquine for https://link.springer.co reducing mortality and Journal Genenral Systematic Arunmozhimaran Chloroquine, 03-sept-20 the Treatment of COVID- India m/article/10.1007/s116 NA improving the clinical Internal Medicine review Elavarasi, et al. hydroxychloroquine 19: a Systematic Review 06-020-06146-w course, fever remission, and Meta-analysis and virologic clearance in COVID-19 patients?
No benefit of Diabetes & hydroxychloroquine in https://www.sciencedire Metabolic COVID-19: Results of Is HCQ effective in milde November - Systematic ct.com/science/article/p Syndrome: Clinical Systematic Review and India Pathak et al. NA hydroxychloroquine to moderate COVID-19 December 2020 review ii/S1871402120303362? Research & Meta-Analysis of patients? via%3Dihub Reviews Randomized Controlled Trials"
Hydroxychloroquine use Naunyn- and progression or https://link.springer.co Schmiedeberg's Systematic Benefits and harms of 06-sept-20 prognosis of COVID-19: a China Zang et al m/article/10.1007%2Fs0 NA hydroxychloroquine Archives of review HCQ in COVID-19 patients systematic review and 0210-020-01964-5 Pharmacology meta-analysis
Effect of Dexamethasone https://jamanetwork.co on Days Alive and To determine whether m/journals/jama/fullarti Ventilator-Free in intravenous cle/2770277?utm_camp Patients With Moderate dexamethasone increases Bruno M. Tomazini, aign=articlePDF&utm_m 02-sept-20 JAMA or Severe Acute RCT Brazil NCT04327401 Dexamethasone the number of ventilator- et al. edium=articlePDFlink&u Respiratory Distress free days among patients tm_source=articlePDF& Syndrome and COVID-19 with COVID- utm_content=jama.2020 The CoDEX Randomized 19–associated ARDS. .17021 Clinical Trial
https://jamanetwork.co Association Between To estimate the m/journals/jama/fullarti Administration of association between Internation cle/2770279?utm_camp PROSPERO Systemic Corticosteroids administration of al aign=articlePDF&utm_m database 02-sept-20 JAMA and Mortality Among Meta-analysis Jonathan A.C., et al. Corticosteroids corticosteroids compared Collaborati edium=articlePDFlink&u (CRD420201972 Critically Ill Patients With with usual care or on tm_source=articlePDF& 42) COVID-19 - A Meta- placebo and 28-day all- utm_content=jama.2020 analysis cause mortality. .17023
https://jamanetwork.co Effect of Hydrocortisone m/journals/jama/fullarti Does low-dose on 21-Day Mortality or cle/2770276?utm_camp hydrocortisone decrease Respiratory Support Pierre-François aign=articlePDF&utm_m treatment failure in 02-sept-20 JAMA Among Critically Ill RCT France NCT02517489 Hydrocortisone Dequin, et al. edium=articlePDFlink&u patients with COVID- Patients With COVID-19 - tm_source=articlePDF& 19–related acute A Randomized Clinical utm_content=jama.2020 respiratory failure? Trial .16761 https://jamanetwork.co Effect of Hydrocortisone m/journals/jama/fullarti on Mortality and Organ cle/2770278?utm_camp To determine whether Support in Patients With Derek C. Angus, et aign=articlePDF&utm_m hydrocortisone improves 02-sept-20 JAMA Severe COVID-19 The RCT UK NCT02735707 Hydrocortisone al. edium=articlePDFlink&u outcome for patients REMAP-CAP COVID-19 tm_source=articlePDF& with severe COVID-19. Corticosteroid Domain utm_content=jama.2020 Randomized Clinical Trial .17022
Convalescent plasma in the management of To assess the moderate COVID-19 in Anup Agarwal et al. effectiveness of India: An open-label https://www.bmj.com/c CTRI/2020/04/0 12 October 2020 BMJ RCT India and PLACID Convalescent plasma Convalescent plasma for parallel-arm phase II ontent/371/bmj.m3939 24775 Collaborators the treatment of COVID- multicentre randomized 19 controlled trial (PLACID Trial)
To demonstrate the efficacy and safety of https://www.medrxiv.or Convalescent Plasma Convalescent Plasma for Avendaño-Solà et g/content/10.1101/2020 used to prevent 01-sept MedRxiv COVID-19: A multicenter, RCT Spain NCT04345523 Convalescent plasma al. .08.26.20182444v3.full.p progression to severe randomized clinical trial df disease or death in hospitalized patients with earlier forms of COVID-19
Early viral clearance Gargling with 1% To assess the ability of among COVID-19 patients https://www.medrxiv.or povidone-iodine regular gargling to when gargling with Nurul Azmawati g/content/10.1101/2020 09-sept MedRxiv RCT Malaysia NCT04410159 (Betadine®), essential eliminate SARS-CoV-2 in Povidone-Iodine and Mohamed et al. .09.07.20180448v1.full.p oils (Listerine®) or tap the oropharynx and Essential oils - a clinical df water nasopharynx. trial.
To investigate whether Tocilizumab in https://www.medrxiv.or tocilizumab has clinical Hospitalized Patients g/content/10.1101/2020 12/09/2020 MedRxiv RCT USA Rosas et al. NCT04320615 Tocilizumab benefit in hospitalized With COVID-19 .08.27.20183442v2.full.p patients with severe Pneumonia df COVID-19 pneumonia.
Efficacy and safety of https://www.sciencedire triazavirin therapy for To assess the efficacy of ct.com/science/article/p ChiCTR2000030 08-sept Engineering coronavirus disease 2019: RCT China Wu et al. Triazavirin Triazavirin (TZV) for Covid- ii/S2095809920302411? 0001 A pilot randomized 19 via%3Dihub controlled trial
Patient-Reported Health To evaluate the efficacy Outcomes After of treatment with Treatment of COVID-19 intravenous and/or with Nebulized and/or https://assets.researchs nebulized neutral Intravenous Neutral quare.com/files/rs- BMC Infectious Delgado-Enciso et neutral electrolyzed electrolyzed saline 10-sept Electrolyzed Saline RCT Cuba 68403/v1/e14a5067- RPCEC00000309 Diseases. al. saline combined with usual Combined with Usual cd36-4094-9c29- medical care versus usual Medical Care Versus 4bb66ac46805.pdf medical care alone, in Usual Medical care alone: ambulatory patients with A Randomized, Open- COVID-19. Label, Controlled Trial. Prediction of respiratory https://www.sciencedire Computers in decompensation in Covid- ct.com/science/article/p 01-sept-20 Biology and 19 patients using RCT USA Burdick et al. NCT04390516 NA NA ii/S0010482520302845? Medicine machine learning: The via%3Dihub READY trial
Effectiveness of remdesivir for the https://onlinelibrary.wil Journal of Medical Remdesivir and its clinical 19-août-20 treatment of hospitalized Review China Jiang et al. ey.com/doi/abs/10.1002 NA Remdesivir Virology effect Covid-19 persons: a /jmv.26443 network meta-analysis
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients https://academic.oup.co Journal of IS sofosbuvir and admitted to hospital with m/jac/advance- 19-août-20 Antimicrobial RCT Iran Sadeghi et al. IRCT202001280 sofosbuvir/daclatasvir dalatasvir effective in moderate or severe article/doi/10.1093/jac/ Chemotherapy 46294N2 COVID patients? coronavirus infection dkaa334/5889948 (COVID-19): a randomized controlled trial
Are human umbilical cord Treatment of severe https://stemcellres.biom umbilical cord mesenchymal stem cell Stem Cell Research COVID-19 with human edcentral.com/articles/1 ChiCTR2000031 18-août-20 RCT China Shu et al. mesenchymal stem infusion effective and & Therapy umbilical cord 0.1186/s13287-020- 494 cells safe for the treatment of mesenchymal stem cells 01875-5 severe COVID?
"Effect of Calcifediol Treatment and best Available Therapy versus Evaluate the effect of best Available Therapy on https://www.sciencedire calcifediol on ICU Journal of Steroid Intensive Care Unit Marta Entrenas ct.com/science/article/p admission and mortality October Biochemistry and RCT Spain NCT04366908 Calcifediol Admission and Mortality Castillo, et al. ii/S0960076020302764? among patients Molecular Biology Among Patients via%3Dihub hospitalized for COVID-19 Hospitalized for COVID- 19: A Pilot Randomized Clinical study
Effect of an Inactivated Vaccine Against SARS- To assess the safety and CoV-2 on Safety and https://jamanetwork.co Vaccine - Phase ChiCTR2000031 immunogenicity of this 13 August 2020 JAMA Immunogenicity China Shengli Xia, et al. m/journals/jama/fullarti Inactivated vaccine I and II 809 whole virus inactivated Outcomes Interim cle/2769612 vaccine Analysis of 2 Randomized Clinical Trials Effect of Remdesivir vs Standard Care on Clinical https://jamanetwork.co Effect of remdesivir in Christoph D. 21 August 2020 JAMA Status at 11 Days in RCT USA m/journals/jama/fullarti NCT04292730 Remdesivir patients with moderate Spinner, et al. Patients With Moderate cle/2769871 COVID19 COVID-19
Drug treatments for covid- Internation Living systematic review 19: living systematic Systematic al Reed AC https://www.bmj.com/c 30 July 2020 BMJ NA All treatments and network meta- review and network meta- Review Collaborati Siemieniuk, et al. ontent/370/bmj.m2980 analysis analysis on
To assess the safety and RNA-Based COVID-19 https://www.medrxiv.or Vaccine: RNA vaccines immunogenicity of Vaccine BNT162b2 USA/ g/content/10.1101/2020 28-août MedRXiv RCT Walsh et al. NCT04368728 BNT162b1 and varying dose levels of Selected for a Pivotal Germany .08.17.20176651v2.full.p BNT162b2 vaccines BNT162b1 and Efficacy Study df BNT162b2.
Methylprednisolone as Adjunctive Therapy for Patients Hospitalized https://academic.oup.co Assess the efficacy of Christiane Maria Clinical Infectious With COVID-19 m/cid/advance- short-term 12 August 2020 RCT Brazil Prado Jeronimo, et NCT04343729 Methylprednisolone Diseases (Metcovid): A article/doi/10.1093/cid/ methylprednisolone in al. Randomised, Double- ciaa1177/5891816 patients with COVID-19 Blind, Phase IIb, Placebo- Controlled Trial
AVIFAVIR for Treatment Assess the efficacy and of Patients with https://academic.oup.co safety of favipiravir in Clinical Infectious Moderate COVID-19: Andrey A. m/cid/advance- moderate COVID19 and 09 August 2020 RCT Russia NCT04434248 Favipiravir Diseases Interim Results of a Phase Ivashchenko, et al. article/doi/10.1093/cid/ select the optimal dosing II/III Multicenter ciaa1176/5890024 regimen for further Randomized Clinical Trial evaluation (Phase III). SARS-CoV-2 Clearance in Efficacy of Novaferon and https://www.sciencedire International COVID-19 Patients with Novaferon + ct.com/science/article/p ChiCTR2000029 Preprint Journal of Novaferon Treatment: A China Fang Zheng, et al. Novaferon Lopinavir/ritonavir in ii/S120197122030597X? 496 Infectious Diseases Randomized, Open-label, moderate and severe via%3Dihub Parallel Group Trial COVID19.
Telmisartan for Assess the anti- treatment of Covid-19 https://www.medrxiv.or Mariano Duarte, et inflammatory effect of Preprint medRxiv patients: an open RCT Argentina g/content/10.1101/2020 NCT04355936 Telmisartan al. telmisartan in COVID-19 randomized clinical trial. .08.04.20167205v2 patients Preliminary report.
Auxora versus standard of care for the treatment https://ccforum.biomed of severe or critical Safety and tolerability of central.com/articles/10. 14 August 2020 Critical Care COVID-19 pneumonia: RCT USA Joseph Miller, et al. NCT04345614. Auxora auxora in severe or 1186/s13054-020-03220- results from a critical COVID-19 x randomized controlled trial
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18- https://www.medrxiv.or Is this SARS CoV 2 Phase II vaccine Preprint medRxiv 59 years: Report of the China Yanjun Zhang, et al. g/content/10.1101/2020 NCT04352608 Inactiviated Vaccine inactivated vaccine safe RCT Randomized, Double- .07.31.20161216v1 and well tolerated? blind, and Placebo- controlled Phase 2 Clinical Trial
Beneficial effects of colchicine for moderate To evaluate the efficacy to severe COVID-19: an https://www.medrxiv.or Maria IF Lopes, et of colcihcine in treating Preprint medRxiv interim analysis of a RCT Brazil g/content/10.1101/2020 RBR-8jyhxh Colchicine al. severe and moderate randomized, double- .08.06.20169573v2 COVID-19 blinded, placebo controlled clinical trial Assess the safety and Phase 1–2 Trial of a SARS- https://www.nejm.org/d NVX-CoV2373; tolerability of the NVX- 2 September CoV-2 Recombinant Spike Phase I vaccine NEJM Australia Cheryl Keech, et al. oi/full/10.1056/NEJMoa NCT04368988 recombinant COV2373 recombinant 2020 Protein Nanoparticle RCT 2026920 nanoparticle vaccine vaccine in healthy Vaccine subjects.
Asses the efficacy of Hydroxychloroquine with https://www.nejm.org/d hydroxychloroquine with or without Azithromycin Alexandre B. 23 July 2020 NEMJ RCT Brazil oi/10.1056/NEJMoa2019 NCT04322123 Hydroxychloroquine and without azithromycin in Mild-to-Moderate Cavalcanti, et al. 014 in mild to moderate Covid-19 COVID19
Systematic Review and Hydroxychloroquine, Meta-analysis of Tocilizumab, Viveksandeep https://onlinelibrary.wil Asses overall efficacy of Journal of Medical Effectiveness of Systematic Remdesivir, 6 July 2020 USA Thoguluva ey.com/doi/epdf/10.100 NA treatments that have Virology Treatment Options review convalescent plasma, Chandrasekar, et al. 2/jmv.26302 been studied thus far. Against SARS-CoV-2 steroids, infection lopinavir/ritonavir
Use of a humanized anti- Is itolizumab a safe and CD6 monoclonal antibody https://www.medrxiv.or efficient treatment for Preprint medRxiv (itolizumab) in elderly CT Cuba Yayquier Díaz, et al. g/content/10.1101/2020 RPCEC00000311 Itolizumab COVID 19 in elderley patients with moderate .07.24.20153833v1 patients? COVID-19
Efficacy and tolerability https://www.medrxiv.or Is bevacizumab a safe of bevacizumab in Preprint medRxiv CT China, Italy Jiaojiao Pang, et al g/content/10.1101/2020 NCT04275414 Bevacizumab and efficient treatment patients with severe .07.26.20159756v1 for severe COVID 19? Covid -19
A clinical pilot study on To evaluate the efficacy the safety and efficacy of https://www.sciencedire and safety of intranasal EClinicalMedicine aerosol inhalation China + ChiCTR2000030 IFN-κ plus trefoil 29 July 2020 CT Weihui et al. ct.com/science/article/p inhalation of TFF2 and (Lancet) treatment of IFN-κ plus USA 262 factor 2 ii/S2589537020302224 IFN-κ protein for SARS- TFF2 in patients with CoV-2 infection moderate COVID-19 A Small-Scale Medication of Leflunomide as a https://link.springer.co ChiCTR Is leflunomide effective in 21 July 2020 Virologica Sinica Treatment of COVID-19 in CT China Hu et al. m/article/10.1007%2Fs1 leflunomide 2000030058 COVID-19 patients? an Open-Label Blank- 2250-020-00258-7 Controlled Clinical Trial
Safety and To assess the immunogenicity of the https://www.thelancet.c immunogenicity, ChAdOx1 nCoV-19 Folegatti et al. on om/journals/lancet/artic ISRCTN reactogenicity, and safety vaccine against SARS-CoV- behalf of the ChAdOx1 nCoV-19 20-juil Lancet RCT UK le/PIIS0140- 15281137; of vaccination with 2: a preliminary report of Oxford COVID vaccine 6736(20)31604- NCT04324606 ChAdOx1 nCoV-19 in a phase 1/2, single-blind, Vaccine Trial Group 4/fulltext single-dose and two-dose randomised controlled regimens. trial
Immunogenicity and Phase 2 trial to further safety of a recombinant evaluate the adenovirus type-5- https://www.thelancet.c immunogenicity and vectored COVID-19 adenovirus type-5 om/action/showPdf?pii= safety in a larger 20-juil Lancet vaccine in healthy adults RCT China Feng-Cai Zhu et al. NCT04341389 (Ad5)-vectored COVID- S0140- population, and to aged 18 years or older: a 19 vaccine 6736%2820%2931605-6 determine an appropriate randomised, double- dose for the efficacy blind, placebo-controlled, study phase 2 trial
To assess safety, tolerability, and Phase 1/2 study of COVID- https://www.nature.co USA/Germ RNA Vaccine immunogenicity of RNA 12 August 2020 Nature 19 RNA vaccine Phase 1/2 trial Mulligan et al. m/articles/s41586-020- NCT04368728 any BNT162b1 Vaccine candidate in a BNT162b1 in adults 2639-4 dose escalation study among healthy adults.
To complement previous reported data by Concurrent human https://www.medrxiv.or providing a detailed NCT04380701, antibody and TH1 type T- Germany/ g/content/10.1101/2020 RNA Vaccine characterisation of 20-juil-20 Medrxiv Phase 1/2 trial Sahin et al. EudraCT: 2020- cell responses elicited by USA .07.17.20140533v1.full.p BNT162b1 antibody and T76 cell 001038-36 a COVID-19 RNA vaccine df immune responses elicited by BNT162b1 vaccination. An mRNA Vaccine against https://www.nejm.org/d To evaluate the safety 14-juil NEMJ SARS-CoV-2 — Phase 1 trial USA Jackson et al. oi/pdf/10.1056/NEJMoa NCT04283461 mRNA-1273 vaccine and immunogenicity of Preliminary Report 2022483 mRNA-1273 vaccine
Effect of Hydroxychloroquine in To assess the safety and Horby et al. Hospitalized Patients with https://www.nejm.org/d ISRCTN efficacy of (RECOVERY 08-oct NEJM COVID-19: Preliminary RCT UK oi/10.1056/NEJMoa2022 50189673, Hydroxychloroquine hydroxychloroquine in Collaborative results from a multi- 926 NCT04381936 patients hospitalized with Group) centre, randomized, COVID-19 controlled trial.
A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and https://www.medrxiv.or To evaluate HCQ efficacy RCT & tolerability of Cheng-Pin Chen et g/content/10.1101/2020 and tolerability in adult 10-juil Medrxiv retrospective Taiwan NCT04384380 Hydroxychloroquine hydroxychloroquine and al. .07.08.20148841v1.full.p patients with mild to cohort study a retrospective study in df moderate COVID-19. adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
To investigate whether Hydroxychloroquine in https://www.acpjournal hydroxychloroquine Annals of Internal Nonhospitalized Adults 16-juil RCT USA Skipper et al. s.org/doi/10.7326/M20- NCT04308668 Hydroxychloroquine could reduce COVID-19 Medicine With Early COVID-19 - A 4207 severity in adult Randomized Trial outpatients
Hydroxychloroquine Is early treatment with Alone or in Combination hydroxychloroquine with Cobicistat-Boosted https://papers.ssrn.com (HCQ) with our without Hydroxychloroquine, Preprint Lancet Darunavir for Treatment RTC Spain Mitjà et al, /sol3/papers.cfm?abstra NCT04304053 cobicistat/darunavir Darunavir, Cobicistat of Mild COVID-19: A ct_id=3615997 more efficacious than no- Cluster-Randomized treatment for outpatients Clinical Trial with mild Covid-19?
To assess the effcacy and safety of A pragmatic randomized https://assets.researchs hydroxychloroquine controlled trial reports quare.com/files/rs- therapy on SARS-CoV-2 the efficacy of Magnus Nakrem Preprint ResearchSquare RCT Norway 44055/v1/3fb11155- NCT04316377 Hydroxychloroquine oropharyngeal viral hydroxychloroquine on Lyngbakken, et al. d83c-48a0-ae74- kinetics in patients coronavirus disease 2019 b3cce9a5eac3.pdf hospitalized with viral kinetics moderately severe COVID- 19. Antiviral Activity and Evaluate the antiviral Safety of activity and safety of Open Forum https://pubmed.ncbi.nl 11 June 2020 Darunavir/Cobicistat for RCT China Jun Chen, et al. NCT04252274 Darunavir, Cobicistat darunavir/cobicistat Infectious Diseases m.nih.gov/32671131/ the Treatment of COVID- (DRV/c) for treating mild 19 COVID-19
lopinavir/ritonavir; arbidol; Systematic and Statistical To assess the current Systematic https://link.springer.co hydroxychloroquine; SN Comprehensive Review of Coronavirus Juan A. Siordia Jr et evidence regarding 15-juil-20 review & Meta- USA m/article/10.1007%2Fs4 N/A remdesivir; Clinical Medicine Disease 19 Treatment al. human controlled COVID- analysis 2399-020-00399-6 tocilizumab; Trials 19 treatment trials. favipiravir; heparin; dexamethasone
https://www.researchga te.net/profile/Abu_Taiu b_Mohammed_Mohiud din_Chowdhury2/public ation/342159343_A_co mparative_observationa Compared outcomes of l_study_on_Ivermectin- Ivermectin-Doxycycline A Randomized Trial of _Doxycycline_and_Hydr vs. Hydroxychloroquine- Abu Taiub Ivermectin, Ivermectin-Doxycycline oxychloroquine- Azithromycin BMC Infectious Banglades Mohammed Doxycycline, Preprint and Hydroxychloroquine- RT Azithromycin_therapy_o NCT04434144 combination therapy Diseases h Mohiuddin Hydroxychloroquine, Azithromycin therapy on n_COVID19_patients/lin COVID19 patients with Chowdhury, et al. Azithromycin COVID19 patients. ks/5f02954c92851c52d6 mild to moderate 19d95e/A-comparative- disease. observational-study-on- Ivermectin-Doxycycline- and-Hydroxychloroquine- Azithromycin-therapy- on-COVID19- patients.pdf
Assess the effectiveness Convalescent plasma or Internation https://www.cochraneli of convalescent plasma hyperimmune Convalescent plasma, updated Systematic al brary.com/cdsr/doi/10.1 and hyperimmune Cochrane immunoglobulin for Piechotta V, et al. NA hyperimmune 12/10/20 review Collaborati 002/14651858.CD01360 immunoglobulin for people with COVID-19: a immunoglobulin on 0.pub2/abstract treating people with living systematic review COVID19
A Randomized, Open- label, Controlled Clinical https://onlinelibrary.wil Efficacy of azvudine in Trial of Azvudine ChiCTR2000029 Preprint Advanced Science RCT China Zhigang Ren, et al. ey.com/doi/epdf/10.100 Azvudine treating mild COVID19 Tablets in the Treatment 853 2/advs.202001435 patients of Mild and Common COVID-19, A Pilot Study Effect of Colchicine vs Standard Care on Cardiac To evaluate the effect of and Inflammatory treatment with colchicine https://jamanetwork.co JAMA Network Biomarkers and Clinical on cardiac and Randomized m/journals/jamanetwor 24/06/2020 Open: Infectious Outcomes in Patients Greece Deftereos et al. NCT04326790 Colchicine inflammatory biomarkers clinical trial kopen/fullarticle/27675 Diseases Hospitalized With and clinical outcomes in 93 Coronavirus Disease patients hospitalized with 2019The GRECCO-19 COVID-19. Randomized Clinical Trial
Febuxostat Therapy in The International Is febuxostat effective in Outpatients With https://pubmed.ncbi.nl IRCT201907270 Hydroxychloroquine, 30-juin-20 Journal of Clinical RCT Iran Davoodi et al. comparision with Suspected COVID-19: A m.nih.gov/32603531/ 4434N1 febuxostat Practice hydroxychloroquine? Clinical Trial
Effect of Dexamethasone To test the effectiveness Horby et al. ISRCTN in Hospitalized Patients of dexamethasone in 17 July 2020 NEMJ RCT UK (RECOVERY Writing https://www.nejm.org/d 50189673, Dexamethasone with COVID-19: patients hospitalized with Committee) oi/pdf/10.1056/NEJMoa NCT04381936 Preliminary Report COVID-19 2021436?casa_token=H 8GAcaEgprUAAAAA:m_9 Qlb5FCP6d6YPLPMryKLq VP0QTUouiQsD39ki_1j8 u1syZDvAET7pLjZ3GbCp QSV4V62JZ8086BOdT
To determine whether a 6-day course of intravenous GLUCOCOVID: A https://www.medrxiv.or methylprednisolone (MP) controlled trial of EudraCT g/content/10.1101/2020 improves outcome in 18-juin medRxiv methylprednisolone in RCT Spain Corral-Gudino et al. number: 2020- methylprednisolone .06.17.20133579v1.full.p patients with SARS CoV-2 adults hospitalized with 001934-37 df infection at risk of COVID-19 pneumonia developing Acute Respiratory Distress Syndrome (ARDS)
Inhibition of Bruton https://immunology.scie Is acalabrutinib effective Science tyrosine kinase in 05-juin-20 RCT USA Roschewski et al. ncemag.org/content/5/4 NA Acalabrutinib in severe COVID-19 Immunology patients with severe 8/eabd0110 patients? COVID-19 Were the non- pharmaceutical Estimating the effects of 8 June 2020 - https://www.nature.co interventions non-pharmaceutical Non-pharmaceutical Accelerated Nature Modelling UK Seth Flaxman, et al. m/articles/s41586-020- NA implemented in European interventions on COVID- interventions publication 2405-7 countries effective in 19 in Europe limiting the spread of SARS CoV-2?
The Janus kinase 1/2 inhibitor ruxolitinib in https://www.nature.co Efficacy and safety of Retrospective 8 May 2020 Nature - Leukemia COVID-19 with severe Germany F. La Rosée, et al. m/articles/s41375-020- Ruxolitinib ruxolitinib in severe analysis systemic 0891-0 COVID19 hyperinflammation
https://www.sciencedire Canakinumab in a Is canakinumab a safe Lancet Retrospective Claudio Ucciferri, et ct.com/science/article/p 8 June 2020 subgroup of patients with Italy NA Canakinumab and effective treatment Reheumatology analysis al. ii/S2665991320301673? COVID-19 against COVID19? via%3Dihub
Use of personal protective equipment To examine the against coronavirus Observational https://www.bmj.com/c protective effects of 10-juin-20 BMJ disease 2019 by China Min Liu et al. NA NA study ontent/369/bmj.m2195 appropriate personal healthcare professionals protective equipment in Wuhan, China: cross sectional study
Effects of non- pharmaceutical https://www.thelancet.c What is the impact of interventions on COVID- om/journals/lanpub/arti The Lancet Digital different control 02-juin-20 19 cases, deaths, and Modelling study UK Gavines et al. cle/PIIS2468- NA NA Healt measures for mitigating demand for hospital 2667(20)30133- the burden of COVID-19 services in the UK: a X/fulltext#%20 modelling study
Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS- https://jcm.asm.org/con Evaluation of Luminex Journal of Clinical Jonathan Hon-Kwan 01-juin-20 CoV-2 detection in Diagnostic Hong-Kong tent/early/2020/05/29/J NA Nucleic acid test NxTAG in COVID-19 Microbiology Chen nasopharyngeal CM.00936-20 detection specimens of COVID-19 patients in Hong Kong Clinical evidence for https://www.sciencedire Clinical repurposing chloroquine Systematic Australia/S ct.com/science/article/p Hydroxychloroquine, Does hydroxychloroquine 26-mai-20 Microbiology and and hydroxychloroquine review / Meta- Rodrigo et al. NA ri Lanka ii/S1198743X20302937? chloroquine have antiviral effect? Infection as antiviral agents: a analysis via%3Dihub systematic review
Kinetics of the humoral To test the performance immune response to https://www.medrxiv.or characteristics of seven SARS-CoV-2: comparative g/content/10.1101/2020 commercially available 14-juin MedRxiv Diagnostic Belgium Herroelen et al. N/A Antibody test analytical performance of .06.09.20124719v2.full.p serology tests for seven commercial df detection of antibodies serology tests against the SARS-CoV-2
Therapeutic effectiveness https://www.medrxiv.or To assess the therapeutic of interferon-alpha 2b observational g/content/10.1101/2020 efficacy of IFN-α2b in 09-juin MedRxiv Cuba Pereda et al. RPCEC00000318 Interferon alpha 2b against COVID-19: the study .05.29.20109199v1.full.p patients infected with Cuban experience df SARS-CoV-2
ICON (Ivermectin in To determine whether COvid Nineteen) study: https://www.medrxiv.or Ivermectin is associated Use of Ivermectin is Retrospective Cepelowicz Rajter g/content/10.1101/2020 10-juin MedRxiv USA N/A Ivermectin with lower mortality rate Associated with Lower analysis et al. .06.06.20124461v2.full.p in patients hospitalized Mortality in Hospitalized df with COVID-19 Patients with COVID19
To assess the efficacy of lenzilumab therapy in First Clinical Use of patients hospitalized with prospective https://www.medrxiv.or Lenzilumab to Neutralize severe COVID-19 study with FDA g/content/10.1101/2020 14-juin MedRxiv GM-CSF in Patients with USA Temesgen et al. N/A Lenzilumab pneumonia, who had emergency use .06.08.20125369v2.full.p Severe and Critical COVID- clinical and/or biomarker IND df 19 Pneumonia evidence for increased risk of progression to respiratory failure.
To investigate whether Low levels of the soluble urokinase prognostic biomarker plasminogen activator https://www.medrxiv.or suPAR are predictive of receptor (suPAR) can aid prospective Denmark/ g/content/10.1101/2020 02-juin MedRxiv mild outcome in patients Eugen-Olsen et al. N/A Prognostic biomarker in identifying patients cohort study USA .05.27.20114678v1.full.p with symptoms of COVID- with low risk of df 19 - a prospective cohort respiratory failure when study presenting with symptoms of COVID-19.
To determine if Low Dose- Low-Dose Whole-Lung https://www.medrxiv.or Radiation Therapy can Radiation for COVID-19 g/content/10.1101/2020 reduce pulmonary 08/06/2020 MedRxiv Pneumonia: Planned Day- CT USA Hess et al. NCT: 04366791 Low dose radiation .06.03.20116988v1.full.p inflammation associated 7 Interim Analysis of a df with COVID-19 Registered Clinical Trial pneumonia.
02-juin MedRxiv Efficacy and Safety of CT China Wang et al. https://www.medrxiv.or ChiCTR2000030 Leflunomide To evaluate the safety To explore the effect of Nano short peptide https://www.medrxiv.or high fiber whey short nutrition intervention on Retrospective g/content/10.1101/2020 08-juin MedRxiv China Zhang et al. N/A enteral nutrition peptide enteral nutrition the prognosis of patients analysis .06.03.20083980v1.full.p on the prognosis of with COVID-19 df patients with COVID-19
To determine if ozonated Ozone therapy for autohemotherapy is https://www.medrxiv.or patients with SARS-COV-2 Spain/ associated with a shorter prospective g/content/10.1101/2020 05-juin MedRxiv pneumonia: a single- USA/Canad Hernández et al. N/A Ozone therapy time to clinical cohort study .06.03.20117994v1.full.p center prospective cohort a improvement in patients df study with severe COVID-19 pneumonia.
To determine the effect CIGB-258 of Center for Genetic immunomodulatory https://www.medrxiv.or Engineering and peptide: a novel Venegas-Rodriguez g/content/10.1101/2020 CIGB-258 immuno- 02-juin MedRxiv CT Cuba RPCEC00000313 Biotechnology (CIGB)-258 promising treatment for et al. .05.27.20110601v1.full.p modulatory peptide therapy in seriously, or critical and severe COVID- df critically ill patients with 19 patients COVID-19.
A cohort study to To determine the clinical evaluate the effect of outcomes of older COVID- combination Vitamin D, https://www.medrxiv.or Vitamin D, 19 patients who received Magnesium and Vitamin Observational Chuen Wen Tan et g/content/10.1101/2020 02-juin MedRxiv Singapore N/A Magnesium and Vitamin D, Magnesium B12 (DMB) on study al. .06.01.20112334v1.full.p Vitamin B12 (DMB) and Vitamin B12 (DMB) progression to severe df compared to those who outcome in older COVID- did not 19 patients.
To evaluate differences in Therapeutic morbidity and mortality Anticoagulation Is https://www.medrxiv.or among mechanically Associated with Retrospective g/content/10.1101/2020 anticoagulation ventilated patients with 03-juin MedRxiv USA Trinh et al. N/A Decreased Mortality in analysis .05.30.20117929v1.full.p agents COVID-19 treated with Mechanically Ventilated df therapeutic versus COVID-19 Patients prophylactic anticoagulation
Tocilizumab for patients https://translational- EudraCT (2020- To evaluate efficacy of with COVID-19 medicine.biomedcentral. 001110-38); 21 OctoberJournal 2020 of Translational Medicine CT Italy Perrone et al. Tocilizumab tocilizumab in COVID-19 pneumonia. The TOCIVID- com/articles/10.1186/s1 clinicaltrials.gov pneumonia patients. 19 phase 2 trial 2967-020-02573-9 (NCT04317092)
To compare SAMBA II SARS-CoV-2 performance Rapid point of care against the standard lab nucleic acid testing for prospective https://www.medrxiv.or RTPCR test in suspected SARS-CoV-2 in clinical trial and UK/South g/content/10.1101/2020 Nucleic acid 02/06/2020 MedRxiv Dami Collier, et al. NCT04326387 COVID-19 cases hospitalised patients: a observational Africa .05.31.20114520v1.full.p diagnostic presenting to hospital, clinical trial and study df followed by a hospital- implementation study based implementation study. To compare three fully automated large-scale laboratory analyzer test Side by side comparison systems, with particular https://www.medrxiv.or of three fully automated emphasis on specificity, Diagnostic g/content/10.1101/2020 06-juin MedRxiv SARS-CoV-2 antibody Austria Perkmann et al. N/A Antibody diagnostic which is crucial for an comparison .06.04.20117911v2.full.p assays with a focus on adequate positive df specificity predictive value given the current low seroprevalence worldwide.
To describe initial experience using a Implementation and commercially-available evaluation of a novel real- https://www.medrxiv.or multiplex two-step time multiplex assay for Diagnostic g/content/10.1101/2020 Nucleic acid 05-juin MedRxiv Australia Williams et al. N/A nested tandem RT-PCR SARS-CoV-2: In-field validation study .06.03.20117267v1.full.p diagnostic assay for the detection of learnings from a clinical df coronaviruses that infect microbiology laboratory humans, including SARS- CoV-2
To construct and validate https://www.medrxiv.or Diagnostic for a cell-free assay to Detection of SARS-CoV-2 Diagnostic USA/Switz g/content/10.1101/2020 indentifying suitable measure neutralizing 02-juin MedRxiv neutralizing antibodies Danh et al. N/A validation study erland .05.28.20105692v1.full.p Convalescent plasma antibodies in order to with a cell-free PCR assay df donors identify suitable donors of convalescent plasma
To evaluate the real- Diagnostic accuracy of a https://www.medrxiv.or diagnostic world diagnostic accuracy host response point-of- g/content/10.1101/2020 ISRCTN1496667 02-juin MedRxiv clinical UK Clark et al. Diagnostic of FebriDx for the care test for identifying .05.27.20114512v1.full.p 3 evaluation identification of COVID- COVID-19 df 19 in hospitalised adults
Alltest rapid lateral flow immunoassays is reliable https://www.sciencedire To analyze the diagnostic in diagnosing SARS-CoV-2 Journal of Clinical ct.com/science/article/p performance of one August 2020 infection from 14 days Diagnostic assay Spain García et al. NA NA Virology ii/S1386653220302158? serologic rapid test in after symptom onset: A via%3Dihub COVID-19 patients prospective single-center study
Poor-sleep is associated with slow recovery from Effects of sleep quality on lymphopenia and an https://www.sciencedire recovery from Brain, Behaviour increased need for ICU Retrospective 06-juin-20 China Zhang et al. ct.com/science/article/p NA NA lymphopenia and clinical and Imunity care in hospitalized study ii/S0889159120309946 outcomes in hospitalized patients with COVID-19: patients with COVID-19 A retrospective cohort study
To assess the overall benefit–risk of the use of Remdesivir in Treatment remdesivir as a treatment of COVID‑19: A Systematic Miranda Davies, et https://doi.org/10.1007/ 28 May 2020 Drug Safety UK NA Remdesivir for COVID-19 compared Systematic Benefit–Risk review al. s40264-020-00952-1 with standard of care, Assessment placebo or other treatments Routine Venous To determine the Thromboembolism frequency of venous Prophylaxis May Be DOI: Venous Society of Critical Observational Thomas K. thromboembolism (VT) in 27 May 2020 Inadequate in the USA 10.1097/CCM.00000000 NA thromboembolism Care study Maatman, et al. critically ill COVID19 Hypercoagulable State of 00004466 prophylaxis patients who recieved Severe Coronavirus prophylaxis for VT. Disease 2019
Effect of Convalescent Plasma Therapy on Time Is convalescent plasma a to Clinical Improvement doi:10.1001/jama.2020. ChiCTR2000029 safe and efficient 3 June 2020 JAMA in Patients With Severe RCT China Ling Li, et al. Convalescent Plasma 10044 757 treatment for severe and Life-threatening COVID19? COVID-19 - A Randomized Clinical Trial
https://www.sciencedire Journal of the To analyze if ramipril Ramipril in High Risk Retrospective Ignacio J. Amat- ct.com/science/article/p NCT03201185 Preprint American College Spain Ramipril modifies the risk for Patients with COVID-19 analysis Santos, et al. ii/S073510972035395X? (source RCT) of Cardiology COVID-19. via%3Dihub
Should health care The need of health policy workeers wear surgical perspective to protect masks or N95 respirators https://journals.plos.org Healthcare Workers Systematic during the routine care Primiano Iannone, /plosone/article?id=10.1 3 June 2020 PlosOne during COVID-19 review / Meta- Italy NA N95 respirators (not et al. 371/journal.pone.02340 pandemic. A GRADE rapid analysis involving aerosol 25 review on the N95 generating procedures) respirators effectiveness of COVID-19 suspected or affected patients?
Physical distancing, face Investigate the effects of masks, and eye physical distance, face protection to prevent Internation PROSPERO: masks, and eye person-to-person Systematic al https://doi.org/10.1016/ 1 June 2020 Lancet Derek K Chu, et al. CRD420201770 PPE protection on virus transmission of SARS-CoV- review collaborati S0140-6736(20)31183-1 47 transmission in health- 2 and COVID-19: a on care and non-health-care systematic review and (eg, community) settings meta-analysis Exposure to DPP-4 inhibitors and COVID-19 Do DPP-4 inhinbitors Diabetes, obesity among people with type Case population Gian Paolo Fadini, https://pubmed.ncbi.nl Preprint Italy NA DPP-4 inhibitors have a protective effect & metabolism 2 study et al. m.nih.gov/32463179/ agains COVID19? diabetes. A case-control study
A Randomized Trial of Is hydroxychloroquine https://www.nejm.org/d Hydroxychloroquine as USA / D.R. Boulware, et effective in post- 03 June 2020 NEJM RCT oi/full/10.1056/NEJMoa NCT04308668. Hydroxychloroquine Postexposure Prophylaxis Canada al. exposure prohylaxis 2016638 for Covid-19 therapy?
Ultra-sensitive and high- Can CRISPR technology Biosensors and throughput CRISPR- https://doi.org/10.1016/ simplify RT-PCR for SARS Preprint Diagnostic assay USA Zhen Huang, et al. NA CRISPR RT-PCR Bioelectronics Powered COVID-19 j.bios.2020.112316 CoV2 and be effective for diagnosis diagnos?
Famotidine Use is Associated with Improved Clinical Outcomes in https://www.gastrojour Do COVID19 patients Hospitalized COVID-19 Retrospective Daniel E. nal.org/article/S0016- taking famotidine have a Preprint Gastroenterology USA NA Famotidine Patients: A Propensity study Freedberg, et al. 5085(20)34706- lower risk of intubation Score Matched 5/fulltext and/or death? Retrospective Cohort Study
Internation Is a 5 day course of Remdesivir for 5 or 10 al https://www.nejm.org/d remedesivir as effective Jason D. Goldman, 27 May 2020 NEJM Days in Patients with RCT collaborati oi/full/10.1056/NEJMoa NCT04292899 Remdesivir as a 10 course in treating et al. Severe Covid-19 on/ Gilead 2015301 moderately ill COVID19 Sciences patients? Internation Is remdesivir an effective Remdesivir for the https://www.nejm.org/d al treatment for reducing 22 May 2020 NEJM Treatment of Covid-19 — J.H. Beigel, et al. J.H. Beigel, et al. oi/full/10.1056/NEJMoa NCT04280705 Remdesivir collaborati time to recovery in Preliminary Report 2007764 on COVID19 patients?
Ruxolitinib in treatment of severe coronavirus To evaluate the efficacy Journal of Allergy disease 2019 (COVID-19): https://doi.org/10.1016/ ChiCTR-OPN- and safety of ruxolitinib Preprint and Clinical RCT China Yang Cao, et al. Ruxolitinib A multicenter, single- j.jaci.2020.05.019 2000029580. for patients with severe Immunology blind, randomized COVID19. controlled trial
Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID 19 by Is thymosin alpha a safe Clinical Infectious Retrospective https://pubmed.ncbi.nl Preprint restoration of China Yueping Liu, et al. NA Thymosin alpha and effective treatment Diseases study m.nih.gov/32442287/ lymphocytopenia and for severe COVID19? reversion of exhausted T cells
HUMAN CORONAVIRUS Level of protection International DATA FROM FOUR https://www.sciencedire C Raina MacIntyre, confered by masks and Preprint Journal of CLINICAL TRIALS OF Review Australia ct.com/science/article/p NA PPE et al. respirators for common Infectious Diseases MASKS AND ii/S1201971220303994 coronavirus. RESPIRATORS
https://www.thelancet.c Use of anakinra in Anakinra for severe om/journals/lanrhe/arti patients who were The Lancet 29-mai-20 forms of COVID-19: a Cohort study France Huet et al. cle/PIIS2665- NA Anakinra admitted to hospital for Rheumatology cohort study 9913(20)30164- severe forms of COVID- 8/fulltext 19 Safety, tolerability, and immunogenicity of a https://www.thelancet.c recombinant adenovirus Are different doses of om/journals/lancet/artic type-5 vectored COVID- Ad5 vectored COVID- Ad5 vectored COVID-19 22-mai-20 The Lancet CT China Feng-Cai Zhu et al. le/PIIS0140- NCT04313127 19 vaccine: a dose- 19 vaccine vaccine safe and 6736(20)31208- escalation, open-label, immunogenic? 3/fulltext non-randomised, first-in- human trial
A comparative study on the time to achieve negative nucleic acid Antiviral effect of https://www.researchsq testing and hospital stays Comparative Zhicheng Zhang et Danopevir and danopevir or 29-mai-20 Preprint China uare.com/article/rs- NA between Danoprevir and study al. lopinavir/ritonavir lopinavir/ritonavir in 28376/v1.pdf Lopinavir/Ritonavir in the COVID-19 patients treatment of patients with COVID-19
Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 https://link.springer.co Current Medical Observational Is Arbidol effective in 01-juin-20 Transmission–A China Zhang et al. m/content/pdf/10.1007/ NA Arbidol Science study profylaxis of COVID? Preliminary Report of a s11596-020-2203-3.pdf Retrospective Cohort Study
Interferon beta-1a as a Advanced Journal Candidate for COVID-19 http://ajem.tums.ac.ir/i Is interferon beta1a IRCT201509140 26-mai-20 of Emergency Treatment; An Open- CT Iran Payandemehr et al. ndex.php/ajem/article/v Interferon beta1a effective in treatment of 24017N1 Medicine label Single-Arm Clinical iew/454/307 COVID-19? Trial
Efficacy and safety of To evaluate efficacy and interferon beta-1a in https://aac.asm.org/con Davoudi-Monfared IRCT201002280 safety of IFN β-1a in 13 July 2020 Antiviral Agents treatment of severe RCT Iran tent/early/2020/07/08/ Interferon beta-1a et al. 03449N28 patients with severe COVID-19: A randomized AAC.01061-20 COVID-19. clinical trial
A serological assay to To develop and clinically https://www.medrxiv.or detect SARS-CoV-2 Clinical evaluate an at-home g/content/10.1101/2020 IRB protocol Antibody diagnostic 30/05/2020 medRxiv antibodies in at-home Evaluation of USA Karp et al. finger-prick dried blood .05.29.20116004v2.full.p #20180015 test collected fingerprick diagnostic test spot test to detect SARS- df dried blood spots CoV-2 antibodies
Performance evaluation To assess the analytical https://www.medrxiv.or of the point-of-care Clinical and clinical performance UK/USA/So g/content/10.1101/2020 Nucleic acid 27/05/2020 medRxiv SAMBA II SARS-CoV-2 Evaluation of Assennato et al. N/A of the SAMBA II 83 SARS- uth Africa .05.24.20100990v2.articl diagnostic test Test for detection of diagnostic test CoV-2 Test using panels e-info SARS-CoV-2 and clinical samples.
To develop and clincally https://www.medrxiv.or EasyCOV : LAMP based Clinical evaluate a new simple g/content/10.1101/2020 saliva RT-LAMP 30/05/2020 medRxiv rapid detection of SARS- Evaluation of France L’Helgouach et al. N/A saliva SARS-CoV-2 .05.30.20117291v1.full.p diagnostic test CoV-2 in saliva diagnostic test detection test based on df RT-LAMP technology
To evaluate the Evaluation of https://www.medrxiv.or performance of two performance of two SARS- Clinical g/content/10.1101/2020 Antibody rapid COVID 19 IgM/IgG Rapid 27/05/2020 medRxiv CoV-2 Rapid whole-blood Evaluation of France Prazuck et al. N/A .05.27.20112888v1.full.p diagnostic test Diagnostic Tests finger-stick IgM-IgG diagnostic test df compared to the gold Combined Antibody Tests standard, RT-PCR.
Mortality reduction in 46 To show the potential severe Covid-19 patients efficacy and safety of https://www.medrxiv.or treated with hyperimmune plasma proof of g/content/10.1101/2020 29/05/2020 medRxiv hyperimmune plasma. A Italy Perotti et al. NCT 04321421 convalescent plasma infusions, obtained from concept study .05.26.20113373v1.full.p proof of concept single convalescent donors, in df arm multicenter COVID-19 patients with interventional trial respiratory failure To analyse the outcomes Use of High Flow Nasal https://www.medrxiv.or of COVID-19 patients Therapy to Treat Retrospective g/content/10.1101/2020 High Flow Nasal with moderate-to-severe 26/05/2020 medRxiv Moderate to Severe USA Patel et al. analysis .05.22.20109355v1.full.p Therapy hypoxemic respiratory Hypoxemic Respiratory df failure receiving High Failure in COVID-19 Flow Nasal Therapy
Hydroxychloroquine or chloroquine with or https://www.thelancet.c without a with or without om/journals/lancet/artic Are these treatment Observational USA/Switz 22-mai-20 The Lancet a macrolide for treatment Mehra et al. le/PIIS0140- NA Hydroxychloroquine regimens associated with study erland of COVID-19: a 6736(20)31180- in-hospital death? multinational registry 6/fulltext analysis
Is Interferon-a2b efficient https://www.frontiersin. Frontiers in Interferon-a2b Treatment Canada, in accelerating viral 15 May 2020 CT Qiong Zhou, et al. org/articles/10.3389/fim NA Interferon-a2b Immunology for COVID-19 China clearance and reducing mu.2020.01061/full inflammation markers?
To examine the role of Early Short Course https://www.medrxiv.or early corticosteroid Clinical Infectious Corticosteroids in Retrospective g/content/10.1101/2020 19 May 2020 USA Fadel et al. NCT04374071 corticosteroids therapy in patients with Diseases Hospitalized Patients with study .05.04.20074609v1.full.p moderate to severe COVID-19 df COVID-19.
Convalescent plasma https://www.medrxiv.or Is convalescent plasma an treatment of severe Preprint medRxiv CT USA Sean T. H. Liu, et al. g/content/10.1101/2020 NA Convalescent plasma effective treatment for COVID-19: A matched .05.20.20102236v1 severe COVID19? control study Use of renin–angiotensin–aldost https://www.thelancet.c erone system inhibitors om/journals/lancet/artic renin–angiotensin–ald Does use of RAAS Case population Francisco J de 14 May 2020 Lancet and risk of COVID-19 Spain le/PIIS0140- EUPAS34437 osterone system predispose patients to study Abajo, et al. requiring admission to 6736(20)31030- inhibitors, RAAS severe COVID19? hospital: a case- 8/fulltext population study
To evaluate various methods of chest Resuscitation of the compressions in patients patient with with suspected/confirmed suspected/confirmed https://journals.viamedi COVID-19 when wearing Randomized SARS-CoV-2 infection Preprint Cardiology Journal Poland Marek Malysz, et al. ca.pl/cardiology_journal NA PPE personal protective crossover trial conducted by medical /article/view/68336 equipment: A students wearing full randomized multicenter personal protective crossover simulation trial equipment (PPE) for aerosol generating procedures (AGP).
Stefano Bonovas, Re-analysis of cumulative Compassionate Use of https://www.nejm.org/d Letters to the Internation Gerd Fätkenheuer, incidence of 15 May 2020 NEJM Remdesivir in Covid-19 oi/full/10.1056/NEJMc2 NA Remdesivir editor al Christian Hoffman, improvement, patient (Grein et al. - NEMJ) 015312 Jiayuan Wu classification
To evaluate the https://www.clinicalmicr performance of an ultra- A multiple center clinical Clinical Diagnostic obiologyandinfection.co fast single-tube nucleic evaluation of an ultra-fast Preprint Microbiology and clinical China Ji Wang, et al. m/action/showPdf?pii=S NA Diagnostic test acid isothermal single-tube assay for Infection evaluation 1198- amplification detection SARS-CoV-2 RNA 743X%2820%2930284-6 assay for SARS-CoV-2 RNA
A combined Are combined oropharyngeal/nares oropharyngeal/nares swab is a suitable https://www.sciencedire Oropharyngeal/nares swab is a suitable Journal of Clinical Diagnostic assay Preprint alternative to Canada Jason J., et al. ct.com/science/article/p NA and nasopharyngeal alternative for Virology comparison nasopharyngeal swabs ii/S1386653220301840 swabs nasopharyngeal swabs for the detection of SARS- for COVID19 sample CoV-2 colleciton? Can an AI model rapidly identify SARS-CoV-2 Artificial infection based on initial https://www.nature.co intelligence–enabled AI diagnostic chest CT scans and 19 May 2020 Nature Diagnostic assay Chinq Xueyan Mei, et al. m/articles/s41591-020- N/A rapid diagnosis of algorithm associated clinical 0931-3 patients with COVID-19 information of COVID-19 (+) patients in the early stage?
To investigate the effects Effects of a DPP-4 dipeptidyl peptidase-4 of dipeptidyl peptidase-4 inhibitor and RAS https://www.medrxiv.or (DPP-4i), (DPP-4i) and blockade on clinical retrospective South Sang Youl Rhee et g/content/10.1101/2020 23-mai Medrxiv N/A renin–angiotensin renin–angiotensin system outcomes of patients analysis Korea al. .05.20.20108555v1.full.p system (RAS) (RAS) blockade on the with diabetes and COVID- df blockade short-term clinical 19 outcomes of COVID-19
Do COVID-19 patients To investigate the https://www.medrxiv.or admitted to the ICU prevalence of prospective g/content/10.1101/2020 anti-Pneumocystis 22-mai Medrxiv require anti- France Alanio N/A Pneumocystis jirovecii in cohort study .05.18.20105296v1.full.p jirovecii prophylaxis Pneumocystis jirovecii COVID-19 patients df prophylaxis? admitted to the ICU
To develop and validate a Development and clinical novel RT-LAMP assay application of a rapid and https://www.medrxiv.or capable of detecting SARS- sensitive loop-mediated RT-LAMP Diagnostic 23/05/2020 Medrxiv Diagnostic China Hu et al. g/content/10.1101/2020 N/A CoV-2 RNA for potential isothermal amplification test .05.20.20108530v2 use in centralized test for SARS-CoV-2 facilities and point-of- infection care settings
Use of siltuximab in https://www.medrxiv.or Efficacy of siltuximab for patients with COVID-19 retrospective g/content/10.1101/2020 22 May 2020 Medrxiv Italy, UK Gritti et al. NCT04322188 siltuximab treatment of severe pneumonia requiring analysis .04.01.20048561v3.full.p patients with COVID-19 ventilatory support df
Almitrine as a non To test if intravenous https://www.medrxiv.or ventilatory strategy to almitrine can improve Case control g/content/10.1101/2020 22-mai Medrxiv improve intrapulmonary France Losser et al. N/A Almitrine hypoxia in mechanically series .05.18.20105502v1.full.p shunt in COVID-19 ventilated COVID-19 df patients patients.
To examine the benefit- Remdesivir in treatment https://www.medrxiv.or risk profile of remdesivir Systematic of COVID-19: A g/content/10.1101/2020 in COVID-19 patients 12-mai MedRxiv benefit-risk UK Davies et al. N/A Remdesivir systematic benefit-risk .05.07.20093898v1.full.p compared to standard assessment assessment df of care, placebo or other treatments. To test the hypothesis Assisting Scalable Application of https://www.medrxiv.or that application of deep Diagnosis Automatically deep learning to g/content/10.1101/2020 learning to 3D chest CT 15-mai MedRxiv China Liu et al. N/A Chest CT via CT Images in the retrospective .05.11.20093732v1.full.p images could help Combat against COVID-19 analysis df identify COVID-19 infections.
To explore the The effects of ARBs, association of ACEi/ARB ACEIs and statins on https://www.medrxiv.or and/or statins with clinical outcomes of retrospective g/content/10.1101/2020 15-mai MedRxiv Belgium De Spiegeleer et al. N/A ARBs, ACEi, Statins clinical manifestations in COVID-19 infection analysis .05.11.20096347v1.full.p COVID-19 infected older among nursing home df people residing in nursing residents homes.
To analyse key safety https://www.medrxiv.or metrics following Early Safety Indicators of expanded g/content/10.1101/2020 transfusion of 14-mai MedRxiv COVID-19 Convalescent access USA Joyner et al. NCT04338360 Convalescent plasma .05.12.20099879v1.full.p convalescent plasma in Plasma in 5,000 Patients program df patients with severe or life-threatening COVID-19
To report the clinical Nebulized in-line course, safety, and endotracheal dornase https://www.medrxiv.or outcomes after nebulized alfa and albuterol Nebulized in-line retrospective g/content/10.1101/2020 in-line endotracheal 15-mai MedRxiv administered to USA Weber et al. NCT04387786 endotracheal Dornase case study .05.13.20087734v1.full.p dornase alfa treatment mechanically ventilated Alfa df for intubated and COVID-19 patients: A mechanically ventilated case series patients with COVID-19.
To determine if Treatment of COVID-19 https://www.medrxiv.or transfusion of Patients with g/content/10.1101/2020 convalescent plasma is a 13-mai MedRxiv Case series USA Salazar et al. N/A Convalescent plasma Convalescent Plasma in .05.08.20095471v1.full.p safe treatment option for Houston, Texas df those with severe COVID- 19 disease.
http://viruseradication.c om/journal- A review of the safety of details/A_review_of_the Journal of Virus favipiravir – a potential Systematic Victoria Pilkington, 30 April 2020 UK _safety_of_favipiravir_% NA Favipiravir Safety of favipiravir Eradication treatment in the COVID- review et al. E2%80%93_a_potential_ 19 pandemic? treatment_in_the_COVI D-19_pandemic%5E/
To evaluate the safety Allogeneic and impact of cardiosphere‑derived administration of cells (CAP‑1002) in https://link.springer.co allogeneic CDCs, Basic Research in Siddharth Singh, et 12 May 2020 critically ill Case series USA m/article/10.1007/s003 NA CAP-1002 formulated for Cardiology al. COVID‑19 patients: 95-020-0795-1 intravenous (IV) compassionate‑use case infusion as CAP-1002, in series critically ill COVID-19 patients. Efficacy and safety of corticosteroids in COVID- 19 based on evidence for COVID-19, other Internation https://www.cmaj.ca/co Assess efficacy and safety Systematic Canadian Medical coronavirus infections, al ntent/cmaj/early/2020/ of corticosteroids for Preprint Review ; Meta- Zhikang Ye, et al. NA Corticosteroids Association Journal influenza, community- Collaborati 05/14/cmaj.200645.full. COVID19, SARS, MERS, analysis acquired pneumonia and on pdf CAP, ARDS and influenza acute respiratory distress syndrome: a systematic review and meta-analysis
Pilot prospective open, Clinical and single-arm multicentre https://www.clinexprhe To assess the efficacy and 1 May 2020 Experimental study on off-label use of CT Italy S. Sciascia, et al. umatol.org/abstract.asp NA Tocilizumab safety of tocilizumab in Rheumatology tocilizumab in patients ?a=15723 severe COVID19 patients with severe COVID-19
Facial protection for Efficacy of different facial healthcare workers Laura R Garcia https://gh.bmj.com/cont protection devices, 23 April 2020 BMJ Global Health Scoping Review USA NA Facial protection during pandemics: a Godoy, et al. ent/5/5/e002553 especially in light of N95 scoping review respirator shortages
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive Comparative efficacy of Pharmacological Spinello Antinori, et https://pubmed.ncbi.nl Preprint care unit (ICU) and Non- Case series Italy NA Remdesivir remdesivir in ICU and non- Research al. m.nih.gov/32407959/ ICU patients: Clinical ICU patients outcome and differences in post treatment hospitalisation status
To evaluate which type of Personal protective full-body PPE and which equipment for preventing method of donning or Internation https://www.cochraneli highly infectious diseases do.ing PPE have the least Systematic al brary.com/cdsr/doi/10.1 15 April 2020 Cochrane Library due to exposure to Verbeek JH, et al. NA PPE risk of contamination or Review Collaborati 002/14651858.CD01162 contaminated body fluids infection for HCW, and on 1.pub4/full in healthcare which training methods staff increase compliance with PPE protocols.
To assess whether Convalescent plasma or convalescent plasma or https://www.cochraneli hyperimmune hyperimmune Systematic Netherland brary.com/cdsr/doi/10.1 14 May 2020 Cochrane Library immunoglobulin for Valk SJ, et al. NA Convalescent Plasma immunoglobulin Review s 002/14651858.CD01360 people with COVID-19: a transfusion is eJective 0/full rapid review and safe in the treatment of people with COVID-19. Preliminary assessment Safety and efficacy of https://www.jacionline. Journal of Allergy of the safety and efficacy early high-dose IV Emanuele Pontali, org/article/S0091- Preprint and Clinical Case series Italy NA Anakinra of anakirna in anakinra in severe COVID- et al. 6749(20)30634- Immunology severe/moderate 19 lung disease 5/fulltext COVID19
Tocilizumab for Treatment of Severe What is the role of COVID-19 Patients: Observational https://pubmed.ncbi.nl tocilizumab therapy in 09 May 2020 Microorganisms Italy Colaneri et al. NA tocilizumab Preliminary Results From study m.nih.gov/32397399/ severe COVID-19 SMAtteo COvid19 patients? REgistry (SMACORE)
Hydroxychloroquine in Patients With Mainly Mild to Moderate https://www.bmj.com/c Is hydroxychloroquine ChiCTR2000029 14 May 2020 BMJ Coronavirus Disease RCT China Tang et al. ontent/369/bmj.m1849.l Hydroxychloroquine effective and safe in 868 2019: Open Label, ong COVID-19 patients? Randomised Controlled Trial
Clinical efficacy of hydroxychloroquine in patients with covid-19 Observational https://www.bmj.com/c Is hydroxychloroquine 05 May 2020 BMJ pneumonia who require France Mahévas et al. NA Hydroxychloroquine study ontent/369/bmj.m1844 effective? oxygen: observational comparative study using routine care data
To assess and compare the performance of 6 Detection of SARS-CoV-2 https://www.medrxiv.or rapid tests and 3 ELISAs antibodies using Clinical g/content/10.1101/2020 Antibody diagnostic for the diagnosis of 08 May 2020 MedRxiv commercial assays and Evaluation of France Tuaillon et al. NCT04347850 .05.04.20090027v3.full.p test COVID-19, and to explore seroconversion patterns diagnostic test df seroconversions in in hospitalized patients subjects with confirmed COVID-19
ddPCR: a more sensitive https://www.medrxiv.or To compare the dynamic Clinical and accurate tool for g/content/10.1101/2020 range and the limit of 08 May 2020 MedRxiv evaluation of China Suo et al. PCR diagnostic test SARS-CoV-2 detection in .02.29.20029439v2.full.p detection (LoD) between diagnostic test low viral load specimens df ddPCR and RT-PCR
Clinical Outcomes and To evaluate the efficacy Plasma Concentrations of https://www.medrxiv.or and safety of adding Baloxavir Marboxil and g/content/10.1101/2020 ChiCTR2000029 baloxavir marboxil, baloxavir marboxil or 05 May 2020 MedRxiv Favipiravir in COVID-19 RCT China Yan Lou et al. .04.29.20085761v1.full.p 544 favipiravir favipiravir to the current Patients: an Exploratory df standard antiviral Randomized, Controlled treatment Trial To determine if excessive https://www.medrxiv.or Celebrex adjuvant PGE2 may be a key in the g/content/10.1101/2020 ChiCTR2000031 11 May 2020 MedRxiv therapy on COVID-19: An Clinical trial China Wenxin Hong et al. Celebrex (Celecoxib) pathology of COVID-19 .05.05.20077610v1.full.p 630 experimental study and whether COX-2 is a df critical target for therapy.
To take into account the possible confounders retrospective https://www.medrxiv.or when analyzing the COVID-19 Related analysis of g/content/10.1101/2020 difference in mortality 05 May 2020 MedRxiv Mortality: Is the BCG Mexico Paredes et al. N/A BCG International .05.01.20087411v1.full.p rates between countries Vaccine Truly Effective? mortality rates df with and without history of a universal BCG vaccination program.
To determine if zinc Hydroxychloroquine and sulfate added to azithromycin plus zinc vs https://www.medrxiv.or zinc sulfate (as add-on retrospective hydroxychloroquine and hydroxychloroquine and g/content/10.1101/2020 therapy to 08 May 2020 MedRxiv observational USA Carlucci et al. N/A azithromycin may azithromycin alone: .05.02.20080036v1.full.p hydroxychloroquine study improve outcomes outcomes in hospitalized df and azithromycin) among hospitalized COVID-19 patients patients.
To evaluate the Efficacy of face mask in https://www.medrxiv.or effectiveness of the use preventing respiratory Systematic g/content/10.1101/2020 of masks to prevent 05 May 2020 MedRxiv virus transmission: a review and China Liang et al. N/A facemask .04.03.20051649v3.full.p laboratory-confirmed systematic review and meta-analysis df respiratory virus meta-analysis transmission.
Impact of corticosteroid Evaluate the safety and therapy on outcomes of https://www.nature.co efficacy of corticosteroids persons with SARS-CoV-2, 5 May 2020 Nature Meta-analyisis China Huan Li, et al. m/articles/s41375-020- NA Corticosteroids on SARS-CoV-2, SARS- SARS-CoV, or MERS-CoV 0848-3.pdf CoV, and MERS-CoV infection: a systematic infections review and meta-analysis
In Silico Trial to test Can an efficient in-silico Journal of https://www.biorxiv.org COVID-19 candidate Giulia Russo, et trial base be developed, Preprint Biomedical and Italy Giulia Russo, et al. /content/10.1101/2020. NA Vaccine vaccines: a case study al. and can it evaluate Health Informatics 05.06.080630v1.full.pdf with UISS platform vaccine candidates?
Were non- Effect of non- pharmaceutical pharmaceutical https://www.nature.co interventions effective in Mathematical China, UK, Non-pharmaceutical Preprint Nature interventions to contain Shengjie Lai, et al. m/articles/s41586-020- NA reducing the number of Modeling US interventions COVID-19 in China 2293-x_reference.pdf cases and speed of the epidemic in mainland China? Continuous hydroxychloroquine or Protective role of colchicine therapy does https://www.ncbi.nlm.ni Autoimmunity Retrospective Omer Gendelman, Colchicine, colchicine or 29 April 2020 not prevent infection Israel h.gov/pmc/articles/PMC NA Reviews analysis et al. hydroxychloroquine hydroxychloriquine for with SARS-CoV-2: Insights 7198406/ COVID19 infection from a large healthcare database analysis
Tocilizumab for the treatment of severe COVID-19 pneumonia https://www.sciencedire Is tocilizumab effective Autoimmunity with hyperinflammatory Observational ct.com/science/article/a for improving respiratory Preprint Italy Paola Toniati, et al. NA Tocilizumab Reviews syndrome and acute study bs/pii/S1568997220301 condition in severe respiratory failure: A 300 COVID19? single center study of 100 patients in Brescia, Italy
https://www.pnas.org/c Effective treatment of Efficacy and safety of Retrospective ontent/pnas/early/2020 April 29 2020 PNAS severe COVID-19 patients China Xiaoling Xua, et al. Tocilizumab tocilizumab in sever analysis /04/27/2005615117.full. with tocilizumab COVID19 pdf
Triple combination of interferon beta-1b, https://www.thelancet.c lopinavir–ritonavir, and om/journals/lancet/artic interferon beta-1b, ribavirin in the treatment The efficacy and safety of 08 May 2020 The Lancet RCT Hong Kong Hung et al. le/PIIS0140- NCT04276688 lopinavir–ritonavir, of patients admitted to combination 6736(20)31042- ribavirin hospital with COVID-19: 4/fulltext an open-label, randomised, phase 2 trial
Interleukin-1 blockade with high-dose anakinra https://www.thelancet.c in patients with COVID- om/journals/lanrhe/arti The Lancet 19, acute respiratory Observational 07 May 2020 Italy Cavalli et al. cle/PIIS2665- NCT04318366 anakinra Efficacy of anakinra Rheumatology distress syndrome, and study 9913(20)30127- hyperinflammation: a 2/fulltext retrospective cohort study
Supportive Treatment https://www.sciencedire Outcomes associated Journal of Clinical with Tocilizumab for Systematic ct.com/science/article/p 19 April 2020 USA Alzghari et al. NA NA with TCZ treatment in Virology COVID-19: A Systematic Review ii/S1386653220301220? patients with COVID-19 Review via%3Dihub
Clinical Microbiology and InfectionUmifenovir treatment is Retrospective China N. Lian, et al. https://www.clinicalmicr NA Umifenovir (Arbidol) not associated with CT obiologyandinfection.co improved outcomes in m/article/S1198- Effectiveness and safety patients with coronavirus 743X(20)30234- 25 April 2020 of umifenovir for disease 2019: A 2/fulltext moderate COVID-19 retrospective study
Journal of Infection Baricitinib therapy in CT Italy Fabrizio Cantini, et https://www.ncbi.nlm.ni NA Baricitinib COVID-19: A pilot study al. h.gov/pmc/articles/PMC Is Baricitinib an effective on safety and clinical 7177073/ drug for clinical and 16 April 2020 impact respiratory improvement in moderate COVID19 patients? medRxiv Mandated Bacillus growth curve USA Berg et al. https://www.medrxiv.or N/A BCG vaccination Calmette-Guérin (BCG) analysis g/content/10.1101/2020 vaccination predicts .04.05.20054163v5.full.p flattened curves for the df spread of COVID-19 Does BCG vaccination 04 May 2020 serve as a protective factor against COVID-19
medRxiv Does TB Vaccination regression USA/ Japan Fukui et al. https://www.medrxiv.or N/A BCG vaccination Reduce COVID-19 analysis based g/content/10.1101/2020 Infection? No Evidence on .04.13.20064287v1.full.p from a Regression observational df To assess the Discontinuity Analysis data effectiveness of BCG 22 April 2020 vaccination against COVID-19
medRxiv A Novel Protein Drug, RCT China Fang Zheng et al. https://www.medrxiv.or ChiCTR2000029 Novaferon, Novaferon, as the g/content/10.1101/2020 496 Lopinavir/Ritonavir Potential Antiviral Drug .04.24.20077735v1.full.p for COVID-19 df To determine the 29 April 2020 antiviral effects of Novaferon for COVID-19
medRxiv Review and Systematic Greece, Fragkou et al. https://www.medrxiv.or N/A all treatment and methodological analysis review France g/content/10.1101/2020 preparation options of trials currently testing .04.27.20080226v1.full.p for covid-19 To summarise the data treatment and df on all currently tested prevention options for treatment and the novel coronavirus prevention options for 01 May 2020 disease (COVID-19) COVID-19, and to globally. methodologically analyse and evaluate the quality of the registered interventional studies
medRxiv Hydroxychloroquine retrospective China Bo Yu et al. https://www.medrxiv.or N/A Hydroxychloroquine application is associated analysis g/content/10.1101/2020 Could with a decreased .04.27.20073379v1.full.p hydroxychloroquine mortality in critically ill df administration be 01 May 2020 patients with COVID-19 beneficial in the treatment of critically ill patients with COVID-19?
medRxiv Hypertension and Renin- retrospective USA Ip et al. https://www.medrxiv.or N/A anti-hypertensive Angiotensin-Aldosterone analysis g/content/10.1101/2020 agents System Inhibitors in .04.24.20077388v1.full.p To determine if anti- Patients with Covid-19 df hypertensive drugs are 29 April 2020 harmful or beneficial to Covid-19 patients with hypertension
medRxiv Lopinavir-ritonavir alone retrospective China Xiu Lan et al. https://www.medrxiv.or N/A lopinavir/ritonavir, To evaluate the antiviral or combined with arbidol analysis g/content/10.1101/2020 arbidol efficacy of in the treatment of 73 .04.25.20079079v1.full.p lopinavir/ritonavir alone 29 April 2020 hospitalized patients with df or combined with arbidol COVID-19: a pilot in the treatment of retrospective study hospitalized patients with COVID-19. medRxiv Preliminary evidence prospective China Mingxing Huang et https://www.medrxiv.or(ChiCTR2000029609 Chloroquine from a multicenter observational al. g/content/10.1101/2020 prospective observational study .04.26.20081059v1.full.p study of the safety and df To assess the efficacy and efficacy of chloroquine safety of chloroquine 04 May 2020 for the treatment of with different doses in COVID-19 COVID-19
medRxiv QT Interval Prolongation retrospective USA/Italy Chorin et al. https://www.medrxiv.or N/A Hydroxychloroquine, and Torsade De Pointes analysis g/content/10.1101/2020 Azithromycin in Patients with COVID-19 .04.27.20074583v1.full.p To evaluate the effects of treated with df Hydroxychloroquine/Azit Hydroxychloroquine/Azit hromycin on the QT 01 May 2020 hromycin interval and the arrhythmic risk in patients with SARS-CoV-2 infection. medRxiv Performance & Quality diagnostic kit China David Surace https://www.medrxiv.or N/A qPCR Diagnostic test Evaluation of Marketed evaluation Kapitula et al. g/content/10.1101/2020 COVID-19 RNA Detection .04.25.20080002v1.full.p Kits df
To assess and compare all nucleic acid-based COVID- 01 May 2020 19 testing kits from quality control perspectives
medRxiv Risk of drug-induced Long Systematic USA/Canad Michaud et al. https://www.medrxiv.or N/A azithromycin, QT Syndrome associated review a g/content/10.1101/2020 chloroquine, with the use of .04.21.20066761v2.full.p favipiravir, repurposed COVID-19 df hydroxychloroquine, drugs: a systematic lopinavir/ritonavir, review remdesivir To determine the relative risk of drug-induced Long QT Syndrome (LQTS) associated with SARS-CoV- 29 April 2020 2 (COVID-19) proposed repurposed drugs compared to well-known torsadogenic compounds
medRxiv Concentration-dependent retrospective Thailand/ Watson et al. https://www.medrxiv.or N/A Chloroquine mortality of chloroquine analysis, UK/ France g/content/10.1101/2020 in overdose Bayesian .04.24.20078303v1.full.p logostic df To evaluate the risk of regression, overdose for chloroquine 29 April 2020 pharmacodyna treatment or prevention mic modelling regimens currently being trialled in COVID19
Remdesivir in adults with https://www.thelancet.c severe COVID-19: a om/journals/lancet/artic Effect of remdesivir in 29 April 2020 The Lancet randomised, double- RCT China Wang et al. le/PIIS0140- NCT04257656 remdesivir COVID-19 patients blind, placebo-controlled, 6736(20)31022- multicentre trial 9/fulltext
A Rapid Systematic Academic Review of Clinical Trials https://onlinelibrary.wil Analyze current literature Systematic 02 May 2020 Emergency Utilizing Chloroquine and USA Chowdhury et al. ey.com/doi/abs/10.1111 NA NA to find the role of CQ and review Medicine Hydroxychloroquine as a /acem.14005 HCQ Treatment for COVID-19.
Clinical Efficacy of Intravenous To determine the clinical https://www.medrxiv.or Immunoglobulin Therapy intravenous efficacy of intravenous retrospective g/content/10.1101/2020 20 April 2020 medRxiv in Critical Patients with China Ziyun Shao et al. N/A immunoglobulin immunoglobulin (IVIG) cohort study .04.11.20061739v2.full.p COVID-19: A Multicenter (IVIG) therapy therapy in COVID-19 df Retrospective Cohort patients. Study
Chloroquine dosing To establish recommendations for https://ascpt.onlinelibra best-evidence to inform Clin Pharmacol pharmacokineti Netherland 22 April 2020 pediatric COVID- Verscheijden et al. ry.wiley.com/doi/10.100 N/A Chloroquine pediatric Chloroquine Ther. c (PBPK) model s 19 supported by 2/cpt.1864 doses for children modeling and simulation. infected with COVID-19
Effect of High vs Low Doses of Chloroquine Diphosphate as To evaluate the safety & Adjunctive Therapy for https://jamanetwork.co efficacy of different JAMA Network Patients Hospitalized m/journals/jamanetwor 24 April 2020 RCT Brazil Borba et al NCT04323527 Chloroquine dosages of chloroquine in Open With Severe Acute kopen/fullarticle/27654 patients with severe Respiratory Syndrome 99 COVID-19. Coronavirus 2 (SARS-CoV- 2) Infection: A Randomized Clinical Trial. A Randomized, Single- blind, Group sequential, Active-controlled Study To evaluate the clinical https://www.medrxiv.or to evaluate the clinical efficacy and safety of α- g/content/10.1101/2020 ChiCTR2000029 21 April 2020 medRxiv efficacy and safety of α- RCT China Zhong et al. α-Lipoic acid (ALA) Lipoic acid (ALA) for .04.15.20066266v1.full.p 851 Lipoic acid for critically ill critically ill patients with df patients with coronavirus COVID-19. disease 2019（COVID- 19）
To systematically retrieve Effectiveness and Safety and summarize the of Glucocorticoids to Rapid review https://www.medrxiv.or current evidence of the 22 April 2020 medRxiv Treat COVID-19: A Rapid and meta- China Shuya Lu et al g/content/10.1101/2020 N/A Glucocorticoids effectiveness and safety Review and Meta- analysis .04.17.20064469v1 of glucocorticoid therapy Analysis for patients with COVID- 19
To assess the A systematic review of https://www.medrxiv.or effectiveness of specific Anakinra, Tocilizumab, Anakinra, Systematic g/content/10.1101/2020 interleukin-1 and -6 26 April 2020 MedRxiv Sarilumab and Siltuximab UK Khan et al N/A Tocilizumab, review .04.23.20076612v1.full.p inhibitors for the for coronavirus-related Sarilumab, Siltuximab df treatment of coronavirus- infections related infections.
https://www.cytodyn.co Southern California Preliminary m/newsroom/press- Patients Treated with results from releases/detail/415/sout Could leronlimab be 13 April 2020 Press release USA CytoDyn INC. NA leronlimab Leronlimab for COVID-19 clinical trial hern-california-patients- effective? under Emergency IND treated-with-leronlimab- for
Transplantation of ACE2- Mesenchymal Stem Cells Efficacy of MSC http://dx.doi.org/10.143 ChiCTR2000029 ACE2-mesenchymal 28 February 2020 Aging and Disease Improves the Outcome of CT China Leng et al. transplantation in COVID 36/AD.2020.0228 990 stem cell Patients with COVID-19 patients Pneumonia
Tocilizumab treatment in https://onlinelibrary.wil What are treatment Journal of Medical Observational 26 March 2020 COVID-19: a single center China Luo et al. ey.com/doi/full/10.1002 NA tocilizumab responses of TCZ in the Virology study experience /jmv.25801 COVID-19 patients?
Association of Inpatient Use of Angiotensin Converting Enzyme To determine the Angiotensin- Inhibitors and association between in- https://www.ahajournal converting enzyme Circulation Angiotensin II Receptor Observational hospital use of ACEI/ARB 17 April 2020 China Zhang et al. s.org/doi/10.1161/CIRCR NA inhibitors (ACEIs) and Research Blockers with Mortality study and all-cause mortality in ESAHA.120.317134 Angiotensin receptor Among Patients With COVID-19 patients with blockers (ARBs) Hypertension hypertension Hospitalized With COVID- 19 Association of Renin- Angiotensin System Inhibitors With Severity Asses the association Angiotensin- or Risk of Death in between ACEIs/ARBs and https://jamanetwork.co converting enzyme Patients With severity of illness and 23 April 2020 JAMA Case series China Juy Li, et al m/journals/jamacardiolo NA inhibitors (ACEIs) and Hypertension mortality in patients with gy/fullarticle/2765049 Angiotensin receptor Hospitalized for hypertension hospitalized blockers (ARBs) Coronavirus Disease 2019 for COVID-19 infection. (COVID-19) Infection inWuhan, China
Potential therapeutic Is treatment with Acta https://www.sciencedire effects of dipyridamole in dipyridamol clinically PrePrint Pharmaceutica RCT China Xiaoyan Liu, et al. ct.com/science/article/p NA Dipyridamole the severely ill patients effetive in severly ill Sinica B ii/S2211383520305529 with COVID-19 COVID19 patients?
Benefits and Risks of Chloroquine and Hydroxychloroquine in https://www.medrxiv.or To evaluate the efficacy The Treatment of Viral meta-analysis of g/content/10.1101/2020 chloroquine/hydroxyc 18 April 2020 medRxiv China/ USA Jing Wang et al and safety of Chloroquine Diseases: A Meta- RCTs .04.13.20064295v1.full.p horoquine and hydroxychloroquine Analysis of Placebo df Randomized Controlled Trials
Physical interventions to To assess the interrupt or reduce the effectiveness of hand spread of respiratory Saudi https://www.medrxiv.or hygiene, surface systematic viruses. Part 2 - Hand Arabia, g/content/10.1101/2020 disinfecting, and other 20 April 2020 medRxiv review and Al-Ansary NA hygiene interventions hygiene and other Australia, .04.14.20065250v1.full.p hygiene interventions in meta-analysis hygiene measures: Canada df preventing or reducing systematic review and the spread of illnesses meta-analysis. from respiratory viruses
An experimental trial of To investigate the recombinant human efficacy and safety of https://www.medrxiv.or interferon alpha nasal Recombinant human recombinant human g/content/10.1101/2020 17 April 2020 medRxiv drops to prevent Clinical trial China Meng et al. NCT04320238 interferon-alpha nasal interferon alpha1b (rhIFN- .04.11.20061473v1.full.p coronavirus disease 2019 drops α) nasal drops in healthy df in medical staff in an medical staff to prevent epidemic area COVID-19.
An exploratory randomized, controlled study on the efficacy and safety of https://www.medrxiv.or Lopinavir-Ritonavir 23 March 2020, lopinavir/ritonavir or g/content/10.1101/2020 lopinavir/ritonavir combination compared to updated 15 April medRxiv RCT China Li et al. NCT04252885 arbidol treating adult .03.19.20038984v2.full.p (Kaletra), arbidol Arbidol compared to no 2020 patients hospitalized with df antiviral treatment mild/moderate COVID-19 (ELACOI) Potential Effectiveness and Safety of Antiviral https://www.medrxiv.or To assess the potential Agents in Children with review and g/content/10.1101/2020 effectiveness and safety 17 April 2020 medRxiv China Shi et al. NA antivirals Coronavirus Disease meta-analysis .04.13.20064436v1.full.p of antiviral agents for 2019: A Rapid Review and df COVID-19 in children. Meta-Analysis
The aim of this review Efficacy and Safety of https://www.medrxiv.or was to evaluate the Antibiotic Agents in g/content/10.1101/2020 17 April 2020 medRxiv rapid review China Wang et al NA antibiotics efficacy and safety of Children with COVID-19: .04.13.20064402v1.full.p antibiotic agents in A Rapid Review df children with COVID-19
No evidence of rapid antiviral clearance or Is hydroxychloroquine clinical ben-efit with the https://www.sciencedire Médécine et effecitve for viral combination of Prospective ct.com/science/article/p Hydroxychloroquine, Preprint Maladies France JM Molina et al. NA clearance when hydroxychloroquine and virological assay ii/S0399077X20300858? azithromycin Infectieuses reproducing the study of azithromycin in patients via%3Dihub Gautrel et al.? with severe COVID-19 infection
Grant from the National Natural Science The effect of Foundation of corticosteroid treatment https://www.sciencedire Evaluate the influence of China (Jing Liu, Accepted 31 on patients with ct.com/science/article/p corticosteroids in Journal of Infection Meta-analysis China Zhenwei Yang, et al. grant no. Corticosteroids March 2020 coronavirus infection: a ii/S0163445320301912? patients with 81472735 ) and systematic review and via%3Dihub coronavirus. the Wuhan meta-analysis University (Jing Liu, grant no. 2042019kf0206
Towards Optimization of https://academic.oup.co What is the best dose of Clinical Infectious Hydroxychloroquine Prospective PK Preprint France Sophie Perinel et al, m/cid/article/doi/10.109 NA Hydroxychloroquine hydroxychloroquine for Diseases Dosing in Intensive Care study 3/cid/ciaa394/5816960 COVID19 patients? Unit COVID-19 Patients
https://academic.oup.co Is cholorquine better Journal of Treating COVID-19 with Mingxing Huang, et m/jmcb/article/doi/10.1 Chloroquine, than lopinavir/ritonavir in Molecular Cell RCT China NA Chloroquine al. 093/jmcb/mjaa014/5814 lopinavir, ritonavir severe and moderate Biology 655 COVID19 patients?
UK, Compassionate Use of https://www.nejm.org/d Canada, 10 April 2020 NEJM Remdesivir for Patients Report Grein et al. oi/full/10.1056/NEJMoa NA Remdesivir NA Europe, with Severe Covid-19 2007016 Japan A systematic review on https://www.sciencedire Summary of the existing Journal of Critical the efficacy and safety of Systematic Andrea Cortegiani, ct.com/science/article/p the evidence on 10 March 2020 Italy NA Chloroquine Care chloroquine for the review et al. ii/S0883944120303907? chloroquine for the treatment of COVID-19 via%3Dihub treatment of COVID-19 Systematic review of the Systematic review of the efficacy and safety of clinical outcomes of using Journal https://onlinelibrary.wil antiretroviral drugs Systematic antiretroviral drugs for Preprint International AIDS Switzerland N Ford et al. ey.com/doi/10.1002/jia2 NA Antiretroviral drugs against SARS, MERS, or review the prevention and Society .25489 COVID-19: initial treatment of assessment coronaviruses and
Ethics Investigate the effects of committees of 6-week respiratory Hainan General Respiratory rehabilitation rehabilitation training on Complementary Non- https://www.sciencedire Hospital and in elderly patients with Respiratory respiratory function, QoL, 30 March 2020 Therapies in interventional China Kai Liu, et al. ct.com/science/article/p Huanggang COVID-19: A randomized rehabilitation training mobility and Clinical Practice RCT ii/S1744388120304278 Central Hospital controlled study psychological function in (approval elderly patients with numbers: 19758 COVID-19 and 20200125)
Investigate the effect of Effects of progressive Complementary Non- https://www.sciencedire Progressive muscle progressive muscle muscle relaxation on 6 March 2020 Therapies in interventional China Kai Liu, et al. ct.com/science/article/p NA relaxation (sleep relaxation on anxiety and anxiety and sleep quality Clinical Practice RCT ii/S1744388120302784 therapy) sleep quality of COVID-19 in patients with COVID-19 patients
First Clinical Study Using https://www.medrxiv.or HCV Protease Inhibitor Effect of danoprevir in g/content/10.1101/2020 24 March 2020 MedRxiv Danoprevir to Treat CT China Chen et al. NCT04291729 danopevir/ritonavir moderate COVID-19 .03.22.20034041v1.full.p Naïve and Experienced patients df COVID-19 Patients
The potential of low molecular weight heparin https://www.medrxiv.or to mitigate cytokine Retrospective 07 April 2020 MedRxiv China Chen Shi et al. g/content/10.1101/2020 not found enoxaparin Efficacy of enoxaparin storm in severe covid-19 CT .03.28.20046144v2 patients: a retrospective clinical study
No evidence of clinical efficacy of hydroxychloroquine in To assess the https://www.medrxiv.or patients hospitalised for effectiveness of Retrospective Matthieu Mahévas g/content/10.1101/2020 14 April 2020 MedRxiv COVID-19 infection and France NA Hydroxychloroquine Hydroxychloroquine in analysis et al. .04.10.20060699v1.full.p requiring oxygen: results patients with severe df of a study using routinely Covid-19 collected data to emulate a target trial Grants: National Science and Technology Major Project (2018ZX107110 01, 2017ZX1010301 1, 2017ZX1020440 1), Sanming Project of Medicine in Shenzhen Is plasma from Treatment of 5 critically https://jamanetwork.co Observational (SZSM20141200 convalescente patients 27 March 2020 JAMA ill patients with COVID-19 China C Shen, et al. m/journals/jama/fullarti Convalescent plasma study 3, beneficial for critically ill with convalescent plasma cle/2763983 SZSM20151200 COVID19 patients? 5), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development
Proceedings of the The feasibility of Is treatment with National Academy Observational/r https://www.pnas.org/c convalescent plasma ChiCTR2000030 convalescent plasma safe 6 April 2020 of Sciences of the etrospective China Kai Duan et al ontent/early/2020/04/0 Convalescent plasma therapy in severe COVID- 048 and beneficial for United States of control 2/2004168117 19 patients: a pilot study COVID19 patients? America
Compare medical masks Medical Masks vs N95 to N95 respirators in Respirators for preventing laboratory Influenza and Preventing COVID-19 in https://onlinelibrary.wil Systematic Jessica J Bartoszko, N95 respirators vs confirmed viral infection Preprint other Respiratory Health Care Workers - A Canada ey.com/doi/pdf/10.1111 NA review et al. surgical masks and respiratory illness Viruses Systematic Review and /irv.12745 including coronavirus Meta-Analysis of specifically in health care Randomized Trials workers.
https://www.cambridge. org/core/journals/disast er-medicine-and-public- RANDOMIZED TRIAL OF health- Is attending one live INSTRUCTOR-LED preparedness/article/ra training session or TRAINING VERSUS VIDEO ndomized-trial-of- watching video trainings Disaster Medicine LESSON IN TRAINING instructorled-training- Training on personal over a month more Preprint and Public Health HEALTH CARE PROVIDERS RCT Denmark L Christensen et al versus-video-lesson-in- NA protective equipment effective for training on Preparedness IN PROPER DONNING training-health-care- downing and doffing AND DOFFING OF providers-in-proper- personal protective PERSONAL PROTECTIVE donning-and-doffing-of- equipment? EQUIPMENT personal-protective- equipment/CF08F4727D A9D536883ECBFD04BC2 570
Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is https://onlinelibrary.wil To assess an easy to Journal of Medical inadequate for diagnosis Irene Cassantini et Diagnostic serological Preprint Diagnostic assay Italy ey.com/doi/epdf/10.100 NA perform serological assay Virology of COVID-19 in acute al. assay 2/jmv.25800 for diagnosis of COVID19 patients referring to emergency room department DOI: 10.1128/JC M.00461-20; Hospital Ethics Evaluation of Committee of Nucleocapsid and Spike https://jcm.asm.org/con Evaluate the diagnostic Joural of Clinical the General Diagnostic serological Preprint Protein-based ELISAs for Diagnostic assay China Wanbing Liu, et al. tent/early/2020/03/27/J feasibility of two ELISA Microbiology Hospital of the assay detecting antibodies CM.00461-20 assays Central Theater against SARS-CoV-2 Command 107 of the PLA ([2020]003-1)
Article originally Australian New A cluster randomised trial To compare the efficacy published in Zealand Clinical of cloth masks compared Australia https://bmjopen.bmj.co medical masks, cloth of cloth masks to medical 2015; authors BMJ Open RCT MacIntyre CR et al. Trials Registry: with medical masks in /Vietnam m/content/5/4/e006577 masks masks in hospital added comment ACTRN1261000 healthcare workers healthcare workers on 30/03/2020 0887077.
Efficacy of hydroxychloroquine in https://www.medrxiv.or ChiCTR2000029 Assess the efficacy of 31 March 2020 MedRxiv patients with COVID-19: RCT China Zhaowei Chen et al. g/content/10.1101/2020 Hydroxychloroquine 559 hydroxychloroquine results of a randomized .03.22.20040758v2 clinical trial
Clinical and microbiological effect of a combination of https://www.mediterran Assess the efficacy of hydroxychloroquine and ee-infection.com/wp- Hydroxychloroquine, hydroxychloroquine Preprint RCT France Gautret et al. NA azithromycin in 80 COVID- content/uploads/2020/0 Azithromycin associated with 19 patients with at least a 3/COVID-IHU-2-1.pdf azithromycin six-day follow up: an observational study
An exploratory randomized, controlled study on the efficacy and safety of Lopinavir-Ritonavir 23 March 2020 https://www.medrxiv.or lopinavir/ritonavir or lopinavir/ritonavir combination compared to (preprint, not yet BMJ RCT China Li et al. g/content/10.1101/2020 NCT04252885 arbidol treating adult (Kaletra), arbidol Arbidol compared to no peer-reviewed) .03.19.20038984v1 patients hospitalized with antiviral treatment mild/moderate COVID-19 (ELACOI) ChiCTR2000029 939, ChiCTR2000029 935, ChiCTR2000029 899, ChiCTR2000029 898, ChiCTR2000029 868, ChiCTR2000029 Breakthrough: 837, Chloroquine phosphate ChiCTR2000029 has shown apparent https://www.jstage.jst.g Summary of 15 826, Could chloroquine be 10 Feb 2020 Biosci Trends efficacy in treatment of China Gao et al. o.jp/article/bst/14/1/14 Chloroquine CTs ChiCTR2000029 effective? COVID-19 associated _2020.01047/_article 803, pneumonia in clinical ChiCTR2000029 studies. 762, ChiCTR2000029 761, ChiCTR2000029 760, ChiCTR2000029 740, ChiCTR2000029 609, ChiCTR2000029 559, and Three Additional Patients https://www.cytodyn.co with Severe COVID-19 Preliminary m/newsroom/press- Treated with Leronlimab results from releases/detail/401/thre Could leronlimab be 30 March 2020 not published yet USA CytoDyn Inc. NA Leronlimab in New York Medical clinical trial e-additional-patients- effective? Center Bringing the Total with-severe-covid-19- to 10 Patients treated-with
Favipiravir versus Arbidol https://www.medrxiv.or ChiCTR2000030 Conventional therapy + 27 March 2020 medRxiv for COVID-19: A RCT China Chang Chen et al. g/content/10.1101/2020 Favipiravir, Arbidol 254 favipiravir or arbidol? Randomized Clinical Trial .03.17.20037432v2
Hydroxychloroquine and International azithromycin as a https://www.sciencedire EudraCT Role of Journal of treatment of COVID-19: ct.com/science/article/p Hydroxychloroquine, 20 March 2020 CT France Gautret et al. number 2020- hydroxychloroquine on Antimicrobial results of an open-label ii/S0924857920300996# Azithromycin 000890-25 respiratory viral loads Agents non-randomized clinical ! trial
A Trial of Lopinavir- https://www.ncbi.nlm.ni Lopinavir-Ritonavir Ritonavir in Adults ChiCTR2000029 lopinavir/ritonavir 19 March 2020 N Engl J Med RCT China Cao et al. h.gov/pubmed/3218746 combination compared to Hospitalized with Severe 308 (Kaletra) 4 conventional therapy ? Covid-19.
Arbidol combined with LPV/r versus LPV/r alone https://www.sciencedire Arbidol and lopinavir- against Corona Virus Retrospective ct.com/science/article/p Lopinavir/ritonavir, 11 March 2020 Journal of Infection China Lisi Deng NA ritonavir compared to Disease 2019: A cohort study ii/S0163445320301134? Arbidol lopinavir-ritonavir only? retrospective cohort via%3Dihub study
High-flow nasal- oxygenation- assisted What is the efficacy and fibreoptic tracheal https://bjanaesthesia.or safety of high-flow nasal British Journal of intubation in critically ill g/article/S0007- ChiCTR2000029 High-flow nasal oxygenation during In press RCT China Cai-Neng Wu et al. Anaesthesia patients with COVID-19 0912(20)30135- 658 oxygnation fibreoptic bronchoscopic pneumonia: a 5/fulltext intubation in critically ill prospective randomised patients with COVID-19? controlled trial Efficacy of lopinavir, Chinese Journal of Efficacy of 2020 Pre-print ritonavir and Arbidol for Retrospective http://rs.yiigle.com/yufa Lopinavir/ritonavir, Infectious China Chen Jun et al. NA lopinavir/ritonavir and online the treatment of new analysis biao/1182592.htm Arbidol Diseases, arbidol coronavirus pneumonia A pilot study of Journal of Zhejiang hydroxychloroquine in http://www.zjujournals. University Role of treatment of patients com/med/CN/10.3785/j. 2020 (Medical Science) RCT China Chen Jun et al. NCT04261517 Hydroxychloroquine hydroxychloroquine on with common issn.1008- 2020 , Vol. 49 respiratory viral loads coronavirus disease-19 9292.2020.03.03 Issue (1) (COVID-19)
Assess the efficacy and Meplazumab treats safety of meplazumab, a COVID-19 pneumonia: an https://doi.org/10.1101/ humanized anti-CD147 2020 Pre-print MedRxiv open-labelled, concurrent CT China Huijie Bian et al. NCT 04275245 Meplazumab 2020.03.21.20040691 antibody, as add-on controlled add-on clinical therapy in patients with trial COVID-19 pneumonia.